0001628280-21-009813.txt : 20210511 0001628280-21-009813.hdr.sgml : 20210511 20210511160526 ACCESSION NUMBER: 0001628280-21-009813 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210511 DATE AS OF CHANGE: 20210511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Foghorn Therapeutics Inc. CENTRAL INDEX KEY: 0001822462 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39634 FILM NUMBER: 21911244 BUSINESS ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE STREET 2: SUITE 700 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-586-3100 MAIL ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE STREET 2: SUITE 700 CITY: CAMBRIDGE STATE: MA ZIP: 02139 10-Q 1 fhtx-20210331.htm 10-Q fhtx-20210331
false2021Q10001822462--12-3100018224622021-01-012021-03-31xbrli:shares00018224622021-04-30iso4217:USD00018224622021-03-3100018224622020-12-31iso4217:USDxbrli:shares00018224622020-01-012020-03-310001822462us-gaap:ConvertiblePreferredStockMember2020-12-310001822462us-gaap:CommonStockMember2020-12-310001822462us-gaap:AdditionalPaidInCapitalMember2020-12-310001822462us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001822462us-gaap:RetainedEarningsMember2020-12-310001822462us-gaap:CommonStockMember2021-01-012021-03-310001822462us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001822462us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001822462us-gaap:RetainedEarningsMember2021-01-012021-03-310001822462us-gaap:ConvertiblePreferredStockMember2021-03-310001822462us-gaap:CommonStockMember2021-03-310001822462us-gaap:AdditionalPaidInCapitalMember2021-03-310001822462us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001822462us-gaap:RetainedEarningsMember2021-03-310001822462us-gaap:ConvertiblePreferredStockMember2019-12-310001822462us-gaap:CommonStockMember2019-12-310001822462us-gaap:AdditionalPaidInCapitalMember2019-12-310001822462us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001822462us-gaap:RetainedEarningsMember2019-12-3100018224622019-12-310001822462us-gaap:CommonStockMember2020-01-012020-03-310001822462us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001822462us-gaap:RetainedEarningsMember2020-01-012020-03-310001822462us-gaap:ConvertiblePreferredStockMember2020-03-310001822462us-gaap:CommonStockMember2020-03-310001822462us-gaap:AdditionalPaidInCapitalMember2020-03-310001822462us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001822462us-gaap:RetainedEarningsMember2020-03-3100018224622020-03-310001822462us-gaap:IPOMember2020-10-272020-10-270001822462us-gaap:IPOMember2020-10-270001822462us-gaap:OverAllotmentOptionMember2020-11-192020-11-190001822462us-gaap:OverAllotmentOptionMember2020-11-1900018224622020-07-012020-07-310001822462us-gaap:USTreasuryNotesSecuritiesMember2021-03-310001822462us-gaap:USTreasuryNotesSecuritiesMember2020-12-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-03-310001822462us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-03-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2021-03-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-03-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2021-03-310001822462us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-03-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2021-03-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-03-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-03-310001822462us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-03-310001822462us-gaap:FairValueMeasurementsRecurringMember2021-03-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-12-310001822462us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2020-12-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2020-12-310001822462us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2020-12-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2020-12-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2020-12-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2020-12-310001822462us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2020-12-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2020-12-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2020-12-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001822462us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001822462us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001822462us-gaap:FairValueMeasurementsRecurringMember2020-12-310001822462us-gaap:EquipmentMember2021-03-310001822462us-gaap:EquipmentMember2020-12-310001822462us-gaap:FurnitureAndFixturesMember2021-03-310001822462us-gaap:FurnitureAndFixturesMember2020-12-310001822462fhtx:ComputerEquipmentAndSoftwareMember2021-03-310001822462fhtx:ComputerEquipmentAndSoftwareMember2020-12-310001822462us-gaap:LeaseholdsAndLeaseholdImprovementsMember2021-03-310001822462us-gaap:LeaseholdsAndLeaseholdImprovementsMember2020-12-310001822462fhtx:AssetsNotYetPlacedInServiceMember2021-03-310001822462fhtx:AssetsNotYetPlacedInServiceMember2020-12-310001822462fhtx:TermLoanAMember2021-03-310001822462fhtx:TermLoanBMemberfhtx:OxfordFinanceLlcMember2020-11-19xbrli:pure0001822462fhtx:OxfordFinanceLlcMember2020-11-190001822462us-gaap:LondonInterbankOfferedRateLIBORMemberfhtx:OxfordFinanceLlcMember2020-11-192020-11-190001822462fhtx:OxfordFinanceLlcMemberfhtx:PrepaymentPeriodOneMember2021-01-012021-03-310001822462fhtx:OxfordFinanceLlcMembersrt:MaximumMemberfhtx:PrepaymentPeriodOneMember2021-01-012021-03-310001822462fhtx:PrepaymentPeriodTwoMemberfhtx:OxfordFinanceLlcMember2021-01-012021-03-310001822462fhtx:PrepaymentPeriodTwoMembersrt:MinimumMemberfhtx:OxfordFinanceLlcMember2021-01-012021-03-310001822462fhtx:PrepaymentPeriodTwoMemberfhtx:OxfordFinanceLlcMembersrt:MaximumMember2021-01-012021-03-310001822462fhtx:OxfordFinanceLlcMemberfhtx:PrepaymentPeriodThreeMember2021-01-012021-03-310001822462srt:MinimumMemberfhtx:OxfordFinanceLlcMemberfhtx:PrepaymentPeriodThreeMember2021-01-012021-03-310001822462fhtx:OxfordFinanceLlcMember2021-03-310001822462fhtx:OxfordFinanceLlcMember2021-01-012021-03-31fhtx:vote0001822462us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001822462us-gaap:EmployeeStockOptionMember2020-01-012020-03-310001822462us-gaap:WarrantMember2021-01-012021-03-310001822462us-gaap:WarrantMember2020-01-012020-03-310001822462us-gaap:ConvertiblePreferredStockMember2021-01-012021-03-310001822462us-gaap:ConvertiblePreferredStockMember2020-01-012020-03-310001822462fhtx:WarrantsOneMember2021-01-012021-03-310001822462fhtx:WarrantsOneMember2020-01-012020-03-310001822462us-gaap:RestrictedStockMember2021-01-012021-03-310001822462us-gaap:RestrictedStockMember2020-01-012020-03-310001822462fhtx:TwoThousandTwentyEquityIncentivePlanMember2020-10-210001822462fhtx:TwoThousandTwentyEquityIncentivePlanMember2021-03-310001822462fhtx:TwoThousandTwentyEquityIncentivePlanMember2021-01-012021-01-010001822462fhtx:TwoThousandTwentyEquityIncentivePlanMember2021-01-012021-03-310001822462fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember2020-10-210001822462fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember2021-03-310001822462fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember2021-01-012021-01-010001822462us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001822462us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-03-310001822462us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001822462us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-03-310001822462fhtx:ResearchDevelopmentAndRegulatoryMembersrt:MaximumMember2021-01-012021-03-310001822462srt:MaximumMemberus-gaap:SalesMember2021-01-012021-03-310001822462fhtx:MerckCollaborationAgreementMember2021-01-012021-03-31utr:sqft0001822462fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember2019-10-310001822462fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMembersrt:ScenarioForecastMember2020-01-012027-12-310001822462fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMembersrt:MaximumMember2019-10-310001822462fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember2021-01-012021-03-310001822462fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember2020-01-012020-03-310001822462fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember2020-01-010001822462fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMemberus-gaap:ScenarioAdjustmentMember2020-06-290001822462fhtx:OfficeSpaceInCambridgeMassachusettsMember2020-04-300001822462fhtx:AdditionalOfficeSpaceInCambridgeMassachusettsMember2021-02-280001822462srt:MaximumMemberfhtx:StanfordLicenseAgreementMember2021-01-012021-03-310001822462fhtx:FlagshipPioneeringMember2015-10-012015-10-310001822462fhtx:FlagshipPioneeringMember2021-01-012021-03-310001822462fhtx:FlagshipPioneeringMember2020-01-012020-03-310001822462fhtx:FlagshipPioneeringMember2021-03-310001822462fhtx:FlagshipPioneeringMember2020-12-310001822462fhtx:ScientificFounderMember2015-10-012015-10-310001822462fhtx:ScientificFounderMember2021-01-012021-03-310001822462fhtx:ScientificFounderMember2020-01-012020-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
______________________
FORM 10-Q
_____________________
(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________________ to __________________
Commission File Number: 001-39634
______________________
Foghorn Therapeutics Inc.
(Exact Name of Registrant as Specified in its Charter)
______________________
Delaware
(State or other jurisdiction of
incorporation or organization)
47-5271393
(I.R.S. Employer
Identification No.)
500 Technology Square, Ste 700
Cambridge MA
(Address of principal executive offices)
02139
(Zip Code)
Registrant’s telephone number, including area code: 617-586-3100
______________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per shareFHTXThe Nasdaq Global Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes x    No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes x    No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer¨Accelerated filer¨
Non-accelerated filerxSmaller reporting companyx
Emerging growth companyx
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes ¨    No x
As of April 30, 2021, the registrant had 36,846,084 shares of common stock, $0.0001 par value per share, outstanding.

Table of Contents

i
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning:
•the initiation, timing, progress and results of our research and development programs, preclinical and clinical studies;
•our ability to advance any product candidates that we may develop and successfully complete preclinical and clinical studies;
•our ability to leverage our initial programs to develop additional product candidates using our Gene Traffic Control platform;
•the impact of the COVID-19 pandemic on our and our collaborators’ business operations, including our research and development programs and preclinical and clinical studies;
•developments related to our competitors and our industry;
•our ability to expand the target populations of our programs and the availability of patients for clinical testing;
•our ability to obtain regulatory approval for FHD-286, FHD-609, and any future product candidates from the U.S. Food and Drug Administration, or FDA, and other regulatory authorities;
•our ability to identify and enter into future license agreements and collaborations;
•our ability to continue to rely on our contract development and manufacturing organizations, or CDMOs, and contract research organizations, or CROs, for our manufacturing and research needs;
•regulatory developments in the United States and foreign countries;
•our ability to attract and retain key scientific and management personnel; and
•the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering FHD-286, FHD-609, our future products and our Gene Traffic Control platform.
The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Moreover, we operate in an evolving environment. New risks and uncertainties may emerge from time to time, and it is not possible for management to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
1
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
Foghorn Therapeutics Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(Unaudited)
March 31,
2021		December 31,
2020
Assets
Current assets:
Cash and cash equivalents
$66,449 $92,795 
Marketable securities94,468 92,975 
Prepaid expenses and other current assets4,398 4,917 
Total current assets165,315 190,687 
Property and equipment, net19,493 19,528 
Restricted cash1,733 1,733 
Other assets1,603 842 
Operating lease right-of-use assets41,742 42,804 
Total assets$229,886 $255,594 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$2,911 $3,680 
Accrued expenses5,126 9,161 
Operating lease liabilities5,783 $3,981 
Financing lease liability105 — 
Deferred revenue2,407 2,024 
        Total current liabilities16,332 18,846 
Notes payable, net of discount and current portion19,739 19,654 
Operating lease liabilities, net of current portion56,548 58,361 
Financing lease liability, net of current portion225 — 
Deferred revenue, net of current portion11,878 12,546 
Total liabilities104,722 109,407 
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 25,000,000 shares authorized at March 31, 2021 and December 31, 2020; no shares issued or outstanding
— — 
Common stock, $0.0001 par value; 175,000,000 shares authorized at March 31, 2021 and December 31, 2020; 36,826,775 shares issued and outstanding at March 31, 2021; 36,790,946 shares issued and outstanding at December 31, 2020
4 4 
Additional paid-in capital311,076 309,126 
Accumulated other comprehensive income (loss)6 (7)
Accumulated deficit(185,922)(162,936)
Total stockholders’ equity$125,164 $146,187 
Total liabilities and stockholders’ equity$229,886 $255,594 
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
Foghorn Therapeutics Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)
Three Months Ended March 31,
20212020
Collaboration revenue
$286 $— 
Operating expenses:
Research and development
18,726 11,503 
General and administrative
4,690 2,221 
Total operating expenses
23,416 13,724 
Loss from operations
(23,130)(13,724)
Other income (expense):
Interest expense
(486)(258)
Interest income and other income (expense), net
630 29 
Change in fair value of preferred stock warrant liability
— 1 
Total other income (expense), net
144 (228)
Net loss$(22,986)$(13,952)
Net loss per share attributable to common stockholders—basic and diluted
$(0.62)$(2.71)
Weighted average common shares outstanding—basic and diluted
36,817,277 5,154,229 
Comprehensive loss:
Net loss$(22,986)$(13,952)
Other comprehensive loss:
Unrealized losses on marketable securities13 — 
Total other comprehensive loss13 — 
Total comprehensive loss$(22,973)$(13,952)
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
Foghorn Therapeutics Inc.
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity
(In thousands, except per share amounts)
(Unaudited)
Series A-1, A-2 and
B Convertible
Preferred Stock
Common StockAdditional
Paid-in
Capital		Accumulated Other Comprehensive Income (Loss)Accumulated
Deficit		Total
Stockholders’
Equity
SharesAmountSharesAmount
Three Months Ended March 31, 2021
Balances at December 31, 2020— $— 36,790,946 $4 $309,126 $(7)$(162,936)$146,187 
Issuance of common stock upon exercise of stock options— — 35,829 — 62 — — 62 
Stock-based compensation expense— — — — 1,888 — — 1,888 
Unrealized gains on marketable securities— — — — — 13 — 13 
Net loss— — — — — — (22,986)(22,986)
Balances at March 31, 2021— $— 36,826,775 $4 $311,076 $6 $(185,922)$125,164 
Three Months Ended March 31, 2020
Balances at December 31, 201928,615,546 $86,544 4,870,851 $— $6,120 $— $(94,136)$(88,016)
Issuance of common stock upon exercise of stock options— — 97,034 — 247 — — 247 
Vesting of restricted stock— — 222,973 — — — — — 
Stock-based compensation expense— — — — 517 — — 517 
Net loss— — — — — — (13,952)(13,952)
Balances at March 31, 202028,615,546 $86,544 5,190,858 $— $6,884 $— $(108,088)$(101,204)
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
Foghorn Therapeutics Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
Three Months Ended March 31,
20212020
Cash flows from operating activities:
Net loss$(22,986)$(13,952)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
1,888 517 
Depreciation and amortization expense
772 255 
Change in fair value of preferred stock warrant liability— (1)
Noncash lease expense1,062 608 
Noncash interest expense85 64 
Accretion of discount on marketable securities(13)— 
Changes in operating assets and liabilities:
Prepaid expenses and other current assets(295)(64)
Accounts payable(754)969 
Accrued expenses and other current liabilities(2,609)(17)
Operating lease liabilities(11)859 
Deferred revenue(286)— 
Net cash used in operating activities(23,147)(10,762)
Cash flows from investing activities:
Purchases of property and equipment(1,794)(1,021)
Purchases of marketable securities(26,467)— 
Proceeds from the sale of marketable securities25,000 — 
Net cash used in investing activities(3,261)(1,021)
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of stock options62 247 
Net cash provided by financing activities62 247 
Net decrease in cash, cash equivalents and restricted cash(26,346)(11,536)
Cash, cash equivalents and restricted cash at beginning of period94,528 17,255 
Cash, cash equivalents and restricted cash at end of period$68,182 $5,719 
Supplemental cash flow information:
Cash paid for interest$400 $190 
Supplemental disclosure of noncash investing and financing information:
Purchases of property and equipment included in accounts payable and accrued expenses$959 $1,471 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$66,449 $3,443 
Restricted cash (current and non-current)1,733 2,276 
Total cash, cash equivalents and restricted cash shown in the statement of cash flows$68,182 $5,719 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
Foghorn Therapeutics Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1.Nature of Business and Basis of Presentation
Foghorn Therapeutics Inc. (the “Company”) is a clinical-stage biopharmaceutical company discovering and developing a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. The Company uses its proprietary Gene Traffic Control platform to identify, validate and potentially drug targets within the system. The Company was founded in October 2015 as a Delaware corporation. The Company is headquartered in Cambridge, Massachusetts.
The Company is subject to risks similar to those of other early-stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, the impact of the COVID-19 pandemic and the need to obtain adequate additional financing to fund the development of its products. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.
In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (“COVID-19”) outbreak a pandemic. The Company’s operations have not been significantly impacted by the COVID-19 pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 outbreak on the Company’s financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s results may be materially adversely affected.
Going concern
On October 27, 2020, the Company completed its initial public offering (“IPO”) pursuant to which it issued and sold 7,500,000 shares of its common stock at a public offering price of $16.00 per share, resulting in net proceeds of $108.0 million, after deducting underwriting discounts and commissions and other offering expenses. On November 19, 2020, the Company issued and sold an additional 951,837 shares of common stock at the IPO price of $16.00 per share pursuant to the underwriters’ partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $14.2 million after deducting underwriting discounts and commissions.
The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations primarily with proceeds from sales of preferred stock, debt financing, an upfront payment of $15.0 million the Company received in July 2020 under a collaboration agreement with Merck Sharp & Dohme Corp. (see Note 9), and most recently, with proceeds from the sale of common stock in the IPO completed in October 2020. The Company has incurred losses since inception and as of March 31, 2021, the Company had an accumulated deficit of $185.9 million. The Company expects to continue to generate operating losses in the foreseeable future. As of the issuance date of these interim condensed consolidated financial statements the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months.
The Company will need to obtain additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborative or strategic alliances or licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or programs. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, pipeline expansion or commercialization efforts, which could adversely affect its business prospects. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all.
6
Basis of presentation
The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Unaudited interim financial information
The accompanying condensed consolidated balance sheet as of March 31, 2021, the condensed consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity and cash flows for the three months ended March 31, 2021 and 2020 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2021 and the results of its operations and its cash flows for the three months ended March 31, 2021 and 2020. The results for the three months ended March 31, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period.
2.Summary of Significant Accounting Policies
The accounting policies of the Company are set forth in Note 2 to the consolidated financial statements contained in the Company’s 2020 Annual Report on Form 10-K. The Company includes herein certain updates to those policies.
Leases

In accordance with ASC 842, Leases, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal or purchase options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company’s policy is to not record leases with an original term of twelve months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company’s existing leases are for office and laboratory space and equipment leases.

In addition to rent, the leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and liability.

Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.

For the Company's financing lease, amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the useful life of the asset or the lease term and is included in operating expenses on the condensed consolidated statements of operations and comprehensive loss. Interest on the finance lease liability is recognized in interest expense on the condensed consolidated statements of operations and comprehensive loss.
Recently issued accounting pronouncements
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to “opt out” of the extended transition related to complying with new or
7
revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company.
3.Marketable Securities and Fair Value Measurements
As of March 31, 2021, available for sale marketable securities by security type consisted of (in thousands):
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
U.S. treasury notes (due within one year)$94,463 $5 $— $94,468 
           Total$94,463 $5 $— $94,468 
As of December 31, 2020, available for sale marketable securities by security type consisted of (in thousands):
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
U.S. treasury notes (due within one year)$92,982 $— $(7)$92,975 
           Total$92,982 $— $(7)$92,975 
The following tables present the Company’s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):
Fair Value Measurements at March 31, 2021 Using:
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds
$66,423 $— $— $66,423 
Marketable securities:
U.S. treasury notes— 94,468 — 94,468 
Total$66,423 $94,468 $— $160,891 
Fair Value Measurements at December 31, 2020 Using:
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds
$48,770 $— $— $48,770 
           U.S. treasury notes— 42,997 — 42,997 
        Marketable securities:
U.S. treasury notes— 92,975 — 92,975 
   Total$48,770 $135,972 $— $184,742 
During the three months ended March 31, 2021 and 2020, there were no transfers between Level 1, Level 2 and Level 3.
8
4.Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
March 31, 2021December 31, 2020
Laboratory equipment$3,998 $3,740 
Furniture and fixtures815 815 
Computer equipment and software100 100 
Leasehold improvements17,024 16,961 
Financing lease right-of-use asset384 — 
Assets not yet placed in service47 15 
22,368 21,631 
Less: Accumulated depreciation and amortization(2,875)(2,103)
19,493 19,528 
Depreciation and amortization expense, including amortization of financing lease right-of-use assets, was $0.8 million and $0.3 million for the three months ended March 31, 2021 and 2020, respectively.
5.Accrued Expenses
Accrued expenses consisted of the following (in thousands):
March 31, 2021December 31, 2020
Accrued employee compensation and benefits$978 $3,513 
Accrued tenant improvements913 2,385 
Accrued external research and development expenses2,477 2,146 
Accrued professional fees620 979 
Other138 138 
$5,126 $9,161 

6.Notes Payable
Long-term debt consisted of the following (in thousands):
March 31, 2021December 31, 2020
Principal amount of long-term debt$20,000 $20,000 
Less: Current portion of long-term debt
— — 
Long-term debt, net of current portion20,000 20,000 
Final payment fee
1,000 1,000 
Debt discount, net of accretion
(1,261)(1,346)
Long-term debt, net of discount and current portion$19,739 $19,654 
As of March 31, 2021, the Company had outstanding loans under its loan and security agreement of $20.0 million.
On November 19, 2020, the Company entered into a loan and security agreement (the "Oxford Loan Agreement"), with Oxford Finance LLC, or Oxford, for an aggregate principal amount of $20.0 million (the "Oxford Term Loan A") and up to an additional $5.0 million (the "Oxford Term Loan B"). On November 19, 2020, the Company borrowed $20.0 million under the Oxford Term Loan A. The Term Loan bears interest at a floating per annum rate equal to the greater of (i) 8.0% and (ii) the sum of (a) thirty-day LIBOR rate plus (b) 7.84%. In addition, upon loan maturity or prepayment, the Company is required to make a final payment fee equal to 5.0% of the aggregate principal amount borrowed which is being amortized to interest expense over the term of the debt using the effective interest method.

9
The Company is required to make monthly interest only payments under the Oxford Loan each month beginning on January 1, 2021. Beginning on December 1, 2023, the Company is required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, based upon a repayment schedule equal to 24 months, with a final maturity date of November 1, 2025 (the “Maturity Date”). At the Company’s option, the Company may elect to prepay the loans subject to a prepayment fee equal to the following percentage of the principal amount being prepaid: 2% if an advance is prepaid during the first 12 months following the applicable advance date, 1% if an advance is prepaid after 12 months but prior to 24 months following the applicable advance date, and 0.5% if an advance is prepaid any time after 24 months following the applicable advance date but prior to the Maturity Date.
The Company's obligations under the Oxford Loan Agreement are secured by a security interest in all of its assets, other than its intellectual property. The Company is also subject to certain affirmative and negative covenants restricting the Company’s activities, including limitations on dispositions, mergers or acquisitions; encumbering its intellectual property; incurring indebtedness or liens; paying dividends; making certain investments; and engaging in certain other business transactions. The obligations under the Loan are subject to acceleration upon the occurrence of specified events of default, including a material adverse change in the Company’s business, operations or financial or other condition. Upon the occurrence of an event of default and until such event of default is no longer continuing, the annual interest rate will be 5.0% above the otherwise applicable rate. As of March 31, 2021 and December 31, 2020, the Company believes an event of default would be remote.
In connection with the Oxford Loan Agreement, the Company granted warrants to purchase 18,445 shares of the Company’s common stock at $16.26 per share. The issued warrants are exercisable for 10 years. The Company valued the warrants using the Black-Scholes option pricing model and determined the fair value of the warrants to be $0.2 million. The Company determined the warrants met the criteria for equity classification, and, as such, the fair value of the warrants were recorded as additional paid-in capital and as a discount to the debt which is being amortized to interest expense over the term of the Oxford Loan of five years. In addition, the Company incurred debt issuance costs of $0.2 million.
As of March 31, 2021, the interest rate applicable to outstanding borrowings under the Oxford Loan Agreement was 8.0%. During the three months ended March 31, 2021, the weighted average effective interest rate on outstanding borrowings was approximately 9.7%.
As of March 31, 2021, future principal payments due are as follows (in thousands):
Remainder of 2021 (nine months)$— 
2022— 
2023833 
202410,000 
2025$9,167 
$20,000 
As of March 31, 2020, the Company had outstanding loans under its amended loan and security agreement with Comerica Bank. In November 2020, the Company used a portion of the proceeds from its new loan and security agreement described above to repay the outstanding principal balances in full plus unpaid accrued interest and the final payment fee.
10
7.Common Stock and Net Loss Per Share
Common Stock
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.
Net Loss Per Share
The following common stock equivalents presented based on amounts outstanding at each period end, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:
March 31,
20212020
Stock options to purchase common stock6,303,254 3,785,380 
Warrants to purchase common stock18,445 — 
Convertible preferred stock (as converted to common stock)— 15,467,863 
Warrants to purchase convertible preferred stock
(as converted to common stock)		— 14,076 
Unvested restricted common stock— 668,920 
6,321,699 19,936,239 
8.Stock-Based Compensation
2016 Stock incentive plan
The Company’s 2016 Stock Incentive Plan, (the “2016 Plan”) provided for the Company to grant incentive stock options or nonqualified stock options and other equity awards to employees, directors and consultants of the Company. Upon the effectiveness of the 2020 Equity Incentive Plan (the “2020 Plan”) in October 2020, the Company ceased granting additional awards under the 2016 Plan.
2020 Equity Incentive Plan
On October 21, 2020, the Company’s board of directors adopted and its stockholders approved the 2020 Plan, which became effective on October 21, 2020. The 2020 Plan provides for the grant of incentive stock options, non-qualified options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The number of shares initially reserved for issuance under the 2020 Plan was (i) 2,200,000 shares (the “share pool”), plus (ii) the number of shares of common stock available for issuance under the 2016 Plan as of the effective date of the 2020 Plan, plus the number of shares of common stock underlying awards under the 2016 Plan that on or after the date of adoption expire or become unexercisable without delivery of shares, are forfeited to, or repurchased for cash, are settled in cash, or otherwise become available again for grant under the 2016 Plan, in each case, in accordance with its terms (up to an aggregate of 5,078,295 shares). As of March 31, 2021, 2,380,492 shares remained available for future grant under the 2020 Plan.
The share pool will automatically increase on January 1 of each year from 2021 to 2030 by the lesser of (i) four percent of the number of shares of our common stock outstanding as of the close of business on the immediately preceding December 31 and (ii) the number of shares determined by the board of directors on or prior to such date for such year. The number of shares reserved for issuance under the 2020 Plan was increased by 1,471,576 shares effective January 1, 2021.
The 2020 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, or its committee if so delegated. Stock options granted with service-based vesting conditions generally vest over four years and expire after ten years. The exercise price for stock options granted is not less than the fair value of common stock on the date of grant. The Company bases fair value of common stock on the quoted market price. Prior to the IPO, the board of directors determined the value the Company’s common stock, taking into consideration its most recently available valuation of common stock performed by third parties as well as additional relevant factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant.
2020 Employee Stock Purchase Plan
On October 21, 2020, the Company’s board of directors adopted and its stockholders approved the 2020 Employee Stock Purchase Plan (the “ESPP”), which became effective on October 21, 2020. The aggregate number of shares of common stock available for purchase pursuant to the exercise of options under the ESPP is 360,000 shares, plus an automatic annual increase, as of January 1 of each year from 2021 to 2030, equal to the lesser of one percent of the number of shares of common stock
11
outstanding as of the close of business on the immediately preceding December 31 and (ii) the number of shares determined by the board of directors on or prior to such date for such year (up to a maximum of 3,220,520 shares). The number of shares reserved for issuance under the ESPP was increased by 367,894 shares effective January 1, 2021.
As of March 31, 2021, no offering periods have commenced under the ESPP.
Stock-based compensation
Stock-based compensation expense was classified in the statements of operations and comprehensive loss as follows (in thousands):
Three Months Ended March 31,
20212020
Research and development expenses$1,014 $327 
General and administrative expenses874 190 
$1,888 $517 
As of March 31, 2021, total unrecognized compensation cost related to unvested options was $26.3 million, which is expected to be recognized over a weighted average period of 3.3 years.
9.Collaboration Agreement
In July 2020, the Company entered into a research collaboration and license agreement (the “Collaboration Agreement”) with Merck Sharp & Dohme Corp. (“Merck”). The Company and Merck will apply Foghorn’s proprietary Gene Traffic Control platform to discover and develop novel therapeutics. Under the Collaboration Agreement, the Company granted Merck exclusive global rights to develop, manufacture and commercialize drugs that target dysregulation of a single transcription factor. Under the terms of the Collaboration Agreement, the Company and Merck are each responsible to perform certain research activities in accordance with a mutually agreed upon research plan. Merck may substitute the selected transcription factor during certain stages of the research program, subject to certain limitations. Following completion of the research program, Merck is responsible for the development and commercialization of the compounds developed pursuant to the research program and any product containing such compounds. Pursuant to the Collaboration Agreement, the Company will also participate on a joint steering committee.
Under the terms of the agreement, Foghorn received a nonrefundable upfront payment of $15.0 million from Merck and is eligible to receive up to $245.0 million upon achievement of specified research, development and regulatory milestones by any product candidate generated by the collaboration, and up to $165.0 million upon achievement of specified sales-based milestones per approved product from the collaboration, if any. The Company will be eligible to receive tiered royalties, calculated on a product-by-product and country-by-country basis, on net sales of approved products from the collaboration, if any, at royalty rates ranging from the mid single digits to low tens, depending on whether the products are covered by patent rights it licenses to Merck.
Unless terminated earlier, the Collaboration Agreement will continue in full force and effect until one or more products has received marketing authorization and, thereafter, until expiration of all royalty obligations under the Collaboration Agreement. The Company or Merck may terminate the Collaboration Agreement upon an uncured material breach by the other party or insolvency of the other party. Merck may also terminate the Merck Collaboration Agreement for any reason upon certain notice to the Company.
The Company determined that the (1) research, development, manufacture and commercialization licenses, (2) the research activities performed by the Company and (3) service on the joint committees represent a single performance obligation under the Collaboration Agreement. The Company determined that Merck cannot benefit from the licenses separately from the research activities and participation on the joint steering committee because these services are specialized and rely on the Company’s expertise such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent one combined performance obligation, and the entire transaction price was allocated to that single combined performance obligation. The performance obligation will be satisfied over the research term as the Company performs the research activities and participates in a joint steering committee to oversee research activities.
The upfront payment of $15.0 million was initially recorded as deferred revenue and is being recognized as revenue as the performance obligation is satisfied. The Company recognizes revenue using the cost-to-cost method, which it believes best depicts the transfer of control to the customer over time. Under the cost-to-cost method, the extent of progress towards
12
completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. As of March 31, 2021, the potential research, development and regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price. Sales-based royalties and milestone payments, which predominantly relate to the license, will be recognized if and when the related sales occur.
As of March 31, 2021, the aggregate amount of the transaction price related to the unsatisfied portion of the performance obligation is $14.3 million, which is expected to be recognized as revenue through 2028. The Company does not expect collaboration revenue to be recognized evenly over this period as it will be recognized on a percentage of completion basis (using cost-to-cost method) as the Company performs the research activities and participates on the joint steering committee, which will likely vary from period to period. In estimating the total costs to satisfy its single performance obligation pursuant to the Collaboration Agreement, the Company is required to make significant estimates including an estimate of the number of transcription factor substitutions and the expected time and expected costs to fulfill the performance obligation. The cumulative effect of revisions to the total estimated costs to complete the Company’s single performance obligation will be recorded in the period in which the changes are identified, and amounts can be reasonably estimated. While such revisions will have no impact on the Company’s cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.
At inception, the Company assessed the Collaboration Agreement to determine whether a significant financing component exists and concluded that a significant financing component does not exist. For the three months ended March 31, 2021, the Company had recorded $0.3 million of revenue under the Collaboration Agreement, which was included in deferred revenue at the beginning of the period.
10.Leases
In October 2019, the Company entered into a lease for 81,441 square feet of office and laboratory space in Cambridge, Massachusetts, commencing in January 2020 (the “New Lease”). The initial term of the New Lease was eight years with a five-year option to extend at fair-market rent at the time of the extension. The base rent payments escalate annually over the eight-year lease term and totaled approximately $60.3 million. In connection with the New Lease, the landlord agreed to fund up to $3.0 million in tenant improvements to the leased facility as well as up to an additional $16.3 million, which resulted in additional rent payments to the landlord over the lease term. During the three months ended March 31, 2021 and 2020, $1.5 million and $0.7 million, respectively, of leasehold improvements were reimbursed by the landlord, which resulted in an increase to operating lease liabilities. The Company will be obligated to pay its portion of real estate taxes and costs related to the premises, including costs of operations and management of the leased premises. On January 1, 2020, the lease commencement date, the Company recorded an operating lease asset of $38.6 million and corresponding lease liability of $38.3 million.
In June 2020, the Company amended the New Lease to defer payment of a portion of the base rent and operating expenses and to extend the lease term by nine months to September 2028. The amendment was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date of June 29, 2020 resulting in an increase of $7.4 million to both the right-of-use asset and lease liabilities.
The Company had a lease for office and laboratory facilities in Cambridge, Massachusetts under a noncancellable operating lease that began in August 2017 and expired in March 2025. In April 2020, this lease was assigned and assumed by a related party which became effective in October 2020.
The components of lease expense were as follows (in thousands):
13
Three Months Ended March 31,
20212020
Operating lease cost$1,887 $1,258 
Short-term lease cost— 27 
Variable lease cost763 236 
$2,650 $1,521 
Supplemental disclosure of cash flow information related to leases was as follows (in thousands):
Three Months Ended March 31,
20212020
Cash paid for amounts included in the measurement of operating lease liabilities$2,371 $456 
Operating lease liabilities arising from obtaining right-of-use assets$— $38,306 
Financing lease liabilities arising from obtaining right-of-use assets$330 $— 
The weighted-average remaining lease term and discount rate as of period ends were as follows:
March 31, 2021December 31, 2020
Weighted-average remaining lease term - operating leases (in years)7.47.7
Weighted-average discount rate - operating leases5.35 %5.35 %
Future annual minimum lease payments under operating leases as of March 31, 2021 were as follows (in thousands):
Remainder of 2021 (nine months)$7,391 
202210,005 
202310,115 
202410,355 
202510,603 
Thereafter30,521 
Total future minimum lease payments
78,990 
Less: imputed interest(14,261)
Less: estimated lease incentives(2,398)
Total operating lease liabilities
$62,331 
Included in the condensed consolidated balance sheet (in thousands):March 31, 2021
Current operating lease liabilities$5,783 
Operating lease liabilities, net of current portion56,548 
Total operating lease liabilities
$62,331 
Sublease agreement
In April 2020, the Company entered into a two-year sublease agreement to sublet approximately 16,843 square feet of office space under the New Lease, as amended, which began in July 2020. In February 2021, the Company entered into an amendment to the sublease to sublet approximately 2,980 square feet of additional office space to the sublessee for the remaining lease term. As of March 31, 2021, the remaining rent payments due to the Company under the amended sublease were $2.6 million. During the three months ended March 31, 2021, the Company recorded other income of $0.6 million related to this sublease.
Financing lease
In October 2020, the Company entered into an equipment lease with a three-year term and an optional purchase option. The Company analyzed the terms of the lease and, due to the likelihood of the Company exercising a purchase option at the end of
14
the three-year lease term, classified this lease as a financing lease. On March 31, 2021, the lease commencement date, the Company recorded a financing lease right-of-use asset of $0.4 million, included in property and equipment, net, and a corresponding financing lease liability of $0.3 million on the condensed consolidated balance sheets. See Notes 2 and 4 for additional information.
11.Commitments and Contingencies
Leases
The Company’s commitments under its leases are described in Note 10.
License agreements
The Company has entered into various exclusive and non-exclusive license agreements for certain technologies. Under the terms of these license agreements, the Company could be required to reimburse the licensors for patent expenses and remit amounts in the low single-digit as sales-based royalties upon the occurrence of specific events as outlined in the corresponding license agreements. The Company is also required to make annual license maintenance fees of less than $0.1 million and pay up to $1.1 million in regulatory milestones on each licensed product upon the occurrence of specific events as outlined in one of the license agreements. None of our product candidates utilize technologies covered by these licenses.
Indemnification agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.
Legal Proceedings
From time to time, the Company may become involved in litigation or other legal proceedings. The Company is not currently a party to any material litigation or legal proceedings.
12.Defined Contribution Plan
The Company has a 401(k) defined contribution plan (the “401(k) Plan”) for its employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits. There was no discretionary match made under the 401(k) Plan as of March 31, 2021.
13.Related Parties
In October 2015, the Company entered into a five-year service agreement with Flagship Pioneering (“Flagship”), an affiliate of one of its stockholders, Flagship Venture Funds, to provide general and administrative services to the Company, including certain consulting services and the provision of employee health and dental benefit plans for the Company’s employees. The Company made no cash payments to Flagship for services received under this during the three months ended March 31, 2021. The Company made cash payments to Flagship for services received under this agreement of $0.2 million during the three months ended March 31, 2020. As of March 31, 2021 and December 31, 2020, the Company had no accounts payable to Flagship. This agreement expired in 2020.
In October 2015, the Company entered into a five-year consulting agreement with a scientific founder of the Company who is also a board member and a shareholder. In October 2020, this agreement was extended to January 1, 2022, with an option to renew. During the three months ended March 31, 2021 and 2020, the Company paid the scientific founder $0.1 million. As of March 31, 2021 and December 31, 2020, the Company had de minimis accounts payable to this scientific founder.


15
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
Overview
We are pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system. Breakdowns in the chromatin regulatory system are associated with over 50 percent of all cancers. Addressing these breakdowns could potentially provide therapies for over 2.5 million patients. Consequently, we are initially focused in oncology. We are developing FHD-286, a selective, allosteric ATPase inhibitor that is currently being evaluated in separate Phase 1 studies in (i) metastatic uveal melanoma and (ii) relapsed and/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We are developing FHD-609, a targeted protein degrader, to treat synovial sarcoma. The investigational new drug application, or IND, for FHD-609 was accepted by the U.S. Food and Drug Administration (FDA) in May 2021. Our vision is to use our Gene Traffic Control platform to discover and develop drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology.

Since our inception in October 2015, we have focused substantially all of our resources on building our Gene Traffic Control platform, organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, protecting our trade secrets, filing patent applications, identifying potential product candidates, undertaking preclinical studies and clinical trial activities, establishing arrangements with third parties for the manufacture of initial quantities of our product candidates and component materials. We do not have any products approved for sale and have not generated any revenue from product sales.

On October 27, 2020, we completed our initial public offering, or IPO, pursuant to which we issued and sold 7,500,000 shares of our common stock at a public offering price of $16.00 per share, resulting in net proceeds of $108.0 million, after deducting underwriting discounts and commissions and other offering expenses. On November 19, 2020, we issued and sold an additional 951,837 shares of common stock at the IPO price of $16.00 per share pursuant to the underwriters’ partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $14.2 million after deducting underwriting discounts and commissions. Prior to our IPO, we have funded our operations with proceeds from sales of preferred stock, term loans and an upfront payment of $15.0 million we received in July 2020 under our collaboration agreement with Merck Sharp & Dohme Corp., or Merck.

We have incurred significant operating losses since our inception. For the three months ended March 31, 2021 and the year ended December 31, 2020, we reported net losses of $23.0 million and $68.8 million, respectively. As of March 31, 2021, we had an accumulated deficit of $185.9 million. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more product candidates we may develop.

We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:

•    advance our FHD-286 and FHD-609 product candidates and continue our preclinical development of product candidates from our current research programs;
•    identify additional research programs and additional product candidates;
•    initiate preclinical testing for any new product candidates we identify and develop;

16
•    obtain, maintain, expand, enforce, defend and protect our trade secrets and intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio;
•    hire additional research and development personnel;
•    add operational, legal, compliance, financial and management information systems and personnel to support our research, product development and operations as a public company;
•    expand the capabilities of our platform;
•    acquire or in-license product candidates, intellectual property and technologies;
•    operate as a public company;
•    seek marketing approvals for any product candidates that successfully complete clinical trials; and
•    ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval.
We will not generate revenue from product sales unless and until we successfully commercialize one of our product candidates, after completing clinical development and obtaining regulatory approval. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, and distribution. Further, we expect to incur additional costs associated with operating as a public company.

As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through our collaboration agreement with Merck and a combination of equity offerings, debt financings and collaborations or licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back our development or commercialization plans for one or more of our product candidates.

Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
COVID-19
In March 2020, COVID-19 was declared a global pandemic by the World Health Organization and to date the COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and are difficult to predict. While we continue to conduct our research and development activities, the COVID-19 pandemic may cause disruptions that affect our ability to initiate and complete preclinical studies, ongoing and future clinical trials or to procure items that are essential for our research and development activities.
We plan to continue to closely monitor the ongoing impact of the COVID-19 pandemic on our employees and our business operations. In an effort to provide a safe work environment for our employees, we have, among other things, increased the cadence of sanitization of our office and lab facilities, implemented various social distancing measures in our office and labs including replacing in-person meetings with virtual interactions, and are providing personal protective equipment for our employees present in our office and lab facilities. We expect to continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees and other business partners in light of the pandemic.
Components of Our Results of Operations
Collaboration Revenue
To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future. If our development efforts for our product candidates are successful and result in regulatory
17
approval or licenses with third parties, we may generate revenue in the future from product sales, milestone payments under our existing collaboration agreement or payments from other license agreements that we may enter into with third parties.
In July 2020, we entered into a strategic research collaboration and license agreement, or the Collaboration Agreement, with Merck, pursuant to which we will apply our proprietary Gene Traffic Control platform to discover and develop novel therapeutics. Under the Collaboration Agreement, we granted Merck exclusive global rights to develop, manufacture, and commercialize drugs that target dysregulation of a single transcription factor. Under the terms of the Collaboration Agreement, we received a nonrefundable upfront payment of $15.0 million from Merck, and are eligible to receive up to $245.0 million upon achievement of specified research, development and regulatory milestones by any product candidate generated by the collaboration, and up to $165.0 million upon achievement of specified sales-based milestones per approved product from the collaboration, if any, as well as royalties on sales of any approved product from the collaboration. We cannot provide assurance as to the timing of future milestone or royalty payments or that we will receive any of these payments at all.
We record revenue over the research term as we satisfy our performance obligation under the Collaboration Agreement. Accordingly, the upfront payment of $15.0 million is being recognized as revenue using the cost-to-cost method, which we believe best depicts the transfer of control to the customer over time. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified single performance obligation. We expect revenue to fluctuate as the achievement of milestones becomes probable and as our efforts to satisfy our performance obligation vary from period to period. In estimating the total costs to satisfy our performance obligation pursuant to the Collaboration Agreement, we are required to make significant estimates including an estimate of the number of transcription factor substitutions and the expected time and expected costs to fulfill the performance obligation. The cumulative effect of revisions to the total estimated costs to complete our performance obligation will be recorded in the period in which the changes are identified, and amounts can be reasonably estimated. While such revisions will have no impact on our cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. During the three months ended March 31, 2021, we recognized $0.3 million of revenue under the Collaboration Agreement and, as of March 31, 2021, we had $14.3 million of deferred revenue related to the upfront payment remaining on our condensed consolidated balance sheets.
Operating Expenses
Our operating expenses are comprised of research and development expenses and general and administrative expenses.
Research and Development Expenses
Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and progressing our programs, which include:
•personnel-related costs, including salaries, benefits and stock-based compensation expense, for employees engaged in research and development functions;
•expenses incurred in connection with our research programs and preclinical and clinical development of our product candidates, including under agreements with third parties, such as consultants and contractors and contract research organizations, or CROs;
•the cost of manufacturing drug substance and drug product for use in our research and preclinical studies and clinical trials under agreements with third parties, such as consultants and contractors and contract development and manufacturing organizations, or CDMOs;
•laboratory supplies and research materials;
•facilities, depreciation and amortization and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance; and
•payments made under third-party licensing agreements.
We track our direct external research and development expenses on a program-by-program basis. These consist of costs that include fees, reimbursed materials, and other costs paid to consultants, contractors, CDMOs, and CROs in connection with our preclinical, clinical and manufacturing activities. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities expenses, including depreciation or other indirect costs, to specific product development programs because these costs are deployed across multiple programs and our platform and, as such, are not separately classified.
18
We expect that our research and development expenses will increase substantially as we advance our programs into clinical development and expand our discovery, research and preclinical activities in the near term and in the future. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any product candidates we may develop. A change in the outcome of any number of variables with respect to product candidates we may develop could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any product candidates we may develop.
General and Administrative Expenses
General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation, for employees engaged in executive, legal, finance and accounting and other administrative functions. General and administrative expenses also include professional fees for legal, patent, consulting, investor and public relations and accounting and audit services as well as direct and allocated facility-related costs.
We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our programs and platform. We also anticipate that we will continue to incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs and investor and public relations expenses associated with operating as a public company.
Other Income (Expense)
Interest Expense
Interest expense consists of interest expense associated with outstanding borrowings under our loan agreements as well as the amortization of debt discount associated with such agreements.
Interest Income and Other Income (Expense), Net
Interest income consists of interest earned on our invested cash balances. Other income (expense) consists of sublease income and miscellaneous expense unrelated to our core operations.
Income Taxes
Since our inception, we have not recorded any income tax benefits for the net losses we have incurred or for the research and development tax credits earned in each period, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards and tax credit carryforwards will not be realized.

As of December 31, 2020, we had federal and state net operating loss carryforwards of $147.3 million and $132.3 million, respectively, which may be available to offset future taxable income. The federal net operating loss carryforwards include $12.5 million which expire at various dates beginning in 2035 and $134.8 million which carryforward indefinitely but in some circumstances may be limited to offset 80% of annual taxable income. The state net operating loss carryforwards expire at various dates beginning in 2036. As of December 31, 2020, we also had federal and state research and development tax credit carryforwards of $3.4 million and $2.0 million, respectively, which may be available to reduce future tax liabilities and expire at various dates beginning in 2036 and 2031, respectively. Due to our history of cumulative net losses since inception and uncertainties surrounding our ability to generate future taxable income, we have recorded a full valuation allowance against our net deferred tax assets at each balance sheet date.

Critical Accounting Policies and Significant Judgments and Estimates

Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

19
While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 as well as elsewhere in this Quarterly Report on Form 10-Q, we believe that revenue recognition, accrued research and development expenses and stock-based compensation are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. There have been no material changes to our critical accounting policies and estimates detailed in the Critical Accounting Policies and Significant Judgements section of Item 7. Managements Discussion and Analysis of financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.



Results of Operations
Comparison of the Three Months Ended March 31, 2021 and 2020
The following table summarizes our results of operations for the three months ended March 31, 2021 and 2020:
Three Months Ended March 31,
20212020Change
(in thousands)
Collaboration revenue$286 $— $286 
Operating expenses:
Research and development
18,726 11,503 7,223 
General and administrative
4,690 2,221 2,469 
Total operating expenses
23,416 13,724 9,692 
Loss from operations(23,130)(13,724)(9,406)
Other income (expense):
Interest expense
(486)(258)(228)
Interest income and other income (expense), net
630 29 601 
Change in fair value of preferred stock warrant liability
— 1 (1)
Total other income (expense), net
144 (228)372 
Net loss$(22,986)$(13,952)$(9,034)
Collaboration Revenue
Collaboration revenue recognized during the three months ended March 31, 2021 of $0.3 million was related to our Collaboration Agreement. The upfront payment of $15.0 million was initially recorded as deferred revenue and is being recognized as revenue under the cost-to-cost method. There was no collaboration revenue recognized during the three months ended March 31, 2020 as the Collaboration Agreement was not entered into until July 2020.
Research and Development Expenses
The following table summarizes our research and development expenses for the three months ended March 31, 2021 and 2020:
20
Three Months Ended March 31,
20212020Change
(in thousands)
Direct research and development expenses by program:
FHD-286
$1,938 $988 $950 
FHD-609
1,398 841 557 
Platform, research and discovery, and unallocated expenses:
Platform and other early stage research external costs
4,458 2,797 1,661 
Personnel related (including stock-based compensation)
6,224 4,250 1,974 
Facility related and other
4,708 2,627 2,081 
Total research and development expenses
$18,726 $11,503 $7,223 
Research and development expenses were $18.7 million for the three months ended March 31, 2021, compared to $11.5 million for the three months ended March 31, 2020. The increase is attributed to an increase in FHD-286 program costs of $1.0 million due to clinical trial start-up costs. The increase in our FHD-609 program costs of $0.6 million was due to IND-enabling activities. Personnel-related costs increased by $2.0 million due primarily to increased headcount in our research and development function. The increase in facility-related expenses and other of $2.1 million was due to the increased costs of supporting a larger research and development organization and their research efforts, including increased rent and maintenance expense related to our new facility lease, and purchases lab supplies, consumables, and equipment.
General and Administrative Expenses
The following table summarizes our general and administrative expenses for the three months ended March 31, 2021 and 2020:
Three Months Ended March 31,
20212020Change
(in thousands)
Personnel related (including stock-based compensation)$2,483 $1,323 $1,160 
Professional and consultant1,099 646 453 
Facility related and other1,108 252 856 
Total general and administrative expenses
$4,690 $2,221 $2,469 
General and administrative expenses were $4.7 million for the three months ended March 31, 2021, compared to $2.2 million for the three months ended March 31, 2020. The increase in personnel-related costs of $1.2 million was primarily a result of an increase in headcount in our general and administrative function to support our business. The increase in professional and consulting costs of $0.5 million was due to increased audit, tax, and consulting services associated with being a publicly traded company. The increase in facility related and other expense of $0.9 million was primarily due to including increased rent, maintenance, and non-capital equipment expense related to our new facility lease.
Other Income (Expense)
Interest expense was $0.5 million for the three months ended March 31, 2021, compared to $0.3 million for the three months ended March 31, 2020. The increase was due to the increased outstanding debt balance as of March 31, 2021 compared to March 31, 2020, resulting from the Oxford Loan.
Interest income and other income (expense), net was $0.6 million for the three months ended March 31, 2021 and consisted primarily of sublease income of $0.6 million related to the sublease that began in July 2020. Interest income and other income (expense), net of a de minimis amount for the three months ended March 31, 2020 consisted primarily of interest income.
Liquidity and Capital Resources
Since our inception in October 2015, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we support our continued research activities and development of our programs and platform. Through March 31, 2021, we have funded our operations with proceeds from our IPO in October 2020, sales of
21
preferred stock, term loans and an upfront payment of $15.0 million we received in July 2020 under our Collaboration Agreement. As of March 31, 2021, we had unrestricted cash, cash equivalents and marketable securities of $160.9 million.
On October 27, 2020, we completed our IPO pursuant to which we issued and sold 7,500,000 shares of our common stock at a public offering price of $16.00 per share, resulting in net proceeds of $108.0 million, after deducting underwriting discounts and commissions and other offering expenses.
On November 19, 2020, we issued and sold an additional 951,837 shares of common stock at the IPO price of $16.00 per share pursuant to the underwriters’ partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $14.2 million after deducting underwriting discounts and commissions.
Cash Flows
The following table summarizes our sources and uses of cash for each of the periods presented:
Three Months Ended March 31,
20212020
(in thousands)
Cash used in operating activities$(23,147)$(10,762)
Cash used in investing activities(3,261)(1,021)
Cash provided by financing activities62 247 
Net increase (decrease) in cash, cash equivalents and restricted cash
$(26,346)$(11,536)
Operating Activities
During the three months ended March 31, 2021, operating activities used $23.1 million of cash, resulting from our net loss of $22.9 million, partially offset by net non-cash charges of $3.8 million and net cash provided by changes in our operating assets and liabilities of $4.0 million. Net cash provided by changes in our operating assets and liabilities for the three months ended March 31, 2021 consisted primarily of a $3.4 million decrease in accounts payable and accrued expenses, an increase of $0.3 million in prepaid expenses and other current assets and a decrease of $0.3 million in deferred revenue resulting from the recognition of revenue on the upfront payment received in connection with our Collaboration Agreement.
During the three months ended March 31, 2020, operating activities used $10.8 million of cash, resulting from our net loss of $14.0 million, partially offset by net non-cash charges of $1.4 million and net cash provided by changes in our operating assets and liabilities of $1.7 million. Net cash provided by changes in our operating assets and liabilities for the three months ended March 31, 2020 consisted primarily of a $1.0 million increase in accounts payable and accrued expenses and other current liabilities and a $0.8 million increase in operating lease liabilities partially offset by an increase of $0.1 million in prepaid expenses and other current assets.
Changes in accounts payable, accrued expenses and other current liabilities and prepaid expenses and other current assets in all periods were generally due to growth in our business, the advancement of our research programs and the timing of vendor invoicing and payments.
Investing Activities
During the three months ended March 31, 2021 net cash used in investing activities was $3.3 million due to $26.5 million of purchases of marketable securities and $1.8 million in purchases of property and equipment partially offset by $25.0 million of sales of marketable securities. Property and equipment purchases for the three months ended March 31, 2021 were primarily related to leasehold improvements for our new facility in Cambridge, Massachusetts.
During the three months ended March 31, 2020, net cash used in investing activities was $1.0 million due to the acquisition of property and equipment during the period. Property and equipment purchases for the three months ended March 31, 2020 were primarily related to leasehold improvements for our new facility in Cambridge, Massachusetts.
Financing Activities
During the three months ended March 31, 2021 and March 31, 2020, net cash provided by financing activities was $0.1 million and $0.2 million, respectively, consisting of net proceeds from the exercise of common stock options for both periods.
22
Loan and Security Agreement with Oxford
On November 19, 2020, we entered into a new loan and security agreement, or the Oxford Loan, with Oxford Finance LLC, or Oxford, for an aggregate principal amount of $20.0 million (Oxford Term Loan A) and up to an additional $5.0 million (Oxford Term Loan B). The Term Loan bears interest at a floating per annum rate equal to the greater of (i) 8.0% and (ii) the sum of (a) thirty-day U.S. DOLLAR LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (b) 7.84%. In addition, upon loan maturity or prepayment, we are required to make a final payment fee equal to 5.0% of the aggregate principal amount borrowed. We are required to make monthly interest only payments under the Oxford Loan on the first calendar day of each month beginning on January 1, 2021. Beginning on December 1, 2023, we are required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, based upon a repayment schedule equal to 24 months, with a final maturity date of November 1, 2025.
Our obligations under the Oxford Loan Agreement will be secured by a security interest in all of our assets, other than our intellectual property. We are also subject to certain affirmative and negative covenants.
Funding Requirements
We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and initiate clinical trials for our product candidates in development. We believe that the net proceeds from our IPO in October 2020, together with our existing cash, cash equivalents and marketable securities, will enable us to fund our operating expenses, capital expenditure requirements and debt service payments into the third quarter of 2022. We have based these estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be inaccurate. We could use our available capital resources sooner than we currently expect, in which case we would be required to obtain additional financing sooner than planned, which may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources.
If we are unable to raise sufficient capital as and when needed, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidate we may develop, or be unable to expand our operations or otherwise capitalize on our business opportunities. If we raise additional funds through collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to future revenue streams or product candidates or grant licenses on terms that may not be favorable to us.
See “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 for additional risks associated with our substantial capital requirements.
Off-balance Sheet Arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission.
Recently Issued Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
We are a smaller reporting company, as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, for this reporting period and are not required to provide the information required under this item.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our management, under the supervision and with the participation of our Principal Executive Officer (our Chief Executive Officer) and Principal Accounting and Financial Officer (our Chief Financial Officer), has evaluated the effectiveness of our
23
disclosure controls and procedures as of period end. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2021, our Principal Executive Officer and Principal Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended March 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
24
PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.
Item 1A. Risk Factors.
For a discussion of potential risks or uncertainties, please see “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Use of Proceeds from Initial Public Offering
On October 27, 2020, we closed our initial public offering, or IPO, of our common stock pursuant to which we issued and sold 7,500,000 shares of our common stock at a price to the public of $16.00 per share for aggregate gross proceeds of $120.0 million, before deducting underwriting discounts and commissions and offering expenses payable by us. On November 19, 2020, we sold an additional 951,837 shares of our common stock pursuant to the underwriters’ option to purchase additional shares in the IPO at the public offering price for an additional $15.2 million in gross proceeds.
All of the shares issued and sold in the IPO were registered under the Securities Act pursuant to the Registration Statement, which was declared effective by the SEC on October 22, 2020. Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Cowen and Company, LLC acted as joint book-running managers and Wedbush Securities Inc. acted as lead manager of our IPO.
We received aggregate net proceeds of approximately $122.2 million after deducting underwriting discounts and commissions and other offering expenses payable by us. None of the underwriting discounts and commissions or offering expenses were incurred or paid to directors or officers of ours or their associates or to persons owning 10 percent or more of our common stock or to any of our affiliates.
We have used approximately $25.0 million of the net proceeds from the IPO as of March 31, 2021 to advance FHD-286 and FHD-609 towards the clinic, to further invest in our pipeline and platform targeting the chromatin regulatory system and for working capital and other general corporate purposes. There has been no material change in our planned use of the net proceeds from the offering as described in our Registration Statement.
25
Item 6. Exhibits.
Exhibit
Number		Description
101.INS*XBRL Instance Document
101.SCH*XBRL Taxonomy Extension Schema Document
101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*XBRL Taxonomy Extension Label Linkbase Document
101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document
______________
*Filed herewith.
**    Furnished herewith.

26
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
FOGHORN THERAPEUTICS, INC.
Date: May 11, 2021By:/s/ Allan Reine
Allan Reine, M.D.
Chief Financial Officer
(Principal Accounting and Financial Officer)

27
 EX-31.1 2 fhtx-20210331xex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Adrian Gottschalk, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Foghorn Therapeutics, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 11, 2021
/s/ Adrian Gottschalk
Adrian Gottschalk
President, Chief Executive Officer and Director
(Principal Executive Officer)


 EX-31.2 3 fhtx-20210331xex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Allan Reine, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Foghorn Therapeutics, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 11, 2021
/s/ Allan Reine
Allan Reine, M.D.
Chief Financial Officer
(Principal Accounting and Financial Officer)


 EX-32.1 4 fhtx-20210331xex321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Foghorn Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: May 11, 2021
/s/ Adrian Gottschalk
Adrian Gottschalk
President, Chief Executive Officer and Director
(Principal Executive Officer)


 EX-32.2 5 fhtx-20210331xex322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Foghorn Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: May 11, 2021
/s/ Allan Reine
Allan Reine, M.D.
Chief Financial Officer
(Principal Accounting and Financial Officer)


 EX-101.SCH 6 fhtx-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements Of Operations And Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Nature of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Nature of Business and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - Marketable Securities and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Marketable Securities and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Available for Sale Marketable Securities By Security Type (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2109104 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 2310302 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment Net (Details) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2113105 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 2314303 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2116106 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 2317304 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 2418407 - Disclosure - Notes Payable - Summary of Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2419408 - Disclosure - Notes Payable - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2420409 - Disclosure - Notes Payable - Summary of Future Principal Payments Due (Details) link:presentationLink link:calculationLink link:definitionLink 2121107 - Disclosure - Common Stock and Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2322305 - Disclosure - Common Stock and Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2423410 - Disclosure - Common Stock and Net Loss Per Share - Earnings Per Share Diluted Anti Dilutive Impact (Details) link:presentationLink link:calculationLink link:definitionLink 2124108 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2325306 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2426411 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2427412 - Disclosure - Stock-Based Compensation - Summary of Stock-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 2128109 - Disclosure - Collaboration Agreement link:presentationLink link:calculationLink link:definitionLink 2429413 - Disclosure - Collaboration Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2130110 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2331307 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2432414 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2433415 - Disclosure - Leases - Summary of Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2434416 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2435417 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2436418 - Disclosure - Leases - Summary of Minimum Lease Payment (Details) link:presentationLink link:calculationLink link:definitionLink 2436418 - Disclosure - Leases - Summary of Minimum Lease Payment (Details) link:presentationLink link:calculationLink link:definitionLink 2437419 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2138111 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2439420 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2140112 - Disclosure - Defined Contribution Plan link:presentationLink link:calculationLink link:definitionLink 2141113 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 2442421 - Disclosure - Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 fhtx-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 fhtx-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 fhtx-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Area of leased property Area of Real Estate Property Long-term Debt Long-term debt, net of discount and current portion Long-term Debt Lessee, Lease, Description Lessee, Lease, Description [Line Items] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Leases Lessee, Operating Leases [Text Block] Document Type Document Type Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accretion of discount on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Related Party [Axis] Related Party [Axis] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Estimated Fair Value Marketable securities Debt Securities, Available-for-sale Equity Components [Axis] Equity Components [Axis] Defined Contribution Plan Retirement Benefits [Text Block] Unvested restricted common stock Restricted Stock [Member] Number of additional shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Minimum Minimum [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Proceeds from the sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Annual license maintenance fees Annual License Maintenance Fees Annual license maintenance fees. Final payment fee Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid Property and equipment, net Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Operating lease liabilities Current operating lease liabilities Operating Lease, Liability, Current Research Development And Regulatory Research Development And Regulatory [Member] Research development and regulatory. Financing lease liabilities arising from obtaining right-of-use assets Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Schedule of Short-term Debt [Table] Schedule of Short-term Debt [Table] Statistical Measurement [Domain] Statistical Measurement [Domain] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Organization Consolidation And Presentation Of Financial Statements Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization consolidation and presentation of financial statements. Entity Interactive Data Current Entity Interactive Data Current Name of each exchange on which registered Security Exchange Name Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Common Stock and Net Loss Per Share Stockholders' Equity Note Disclosure [Text Block] Office and Laboratory Space In Cambridge, Massachusetts Office and Laboratory Space In Cambridge, Massachusetts [Member] Office and Laboratory Space In Cambridge, Massachusetts Accrued external research and development expenses Accrued Research And Development Expenses Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Financing lease right-of-use asset Finance Lease, Right-of-Use Asset, before Accumulated Amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract] Loss from operations Operating Income (Loss) Payment of notes payable issuance costs Payments of Debt Issuance Costs Voting rights per share (per share) Common Stock, Voting Rights, Votes Common Stock, Voting Rights, Votes Total current liabilities Liabilities, Current Entity Registrant Name Entity Registrant Name Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Weighted-average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Variable Rate [Domain] Variable Rate [Domain] Accrued professional fees Accrued Professional Fees, Current Variable Rate [Axis] Variable Rate [Axis] Commitments and contingencies (Note 11) Commitments and Contingencies Assets Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounting Policies [Abstract] Accounting Policies [Abstract] Furniture and fixtures Furniture and Fixtures [Member] Entity Address, State Entity Address, State or Province Cash paid for amounts included in the measurement of operating lease liabilities Operating Lease, Payments Accounts payable Accounts Payable, Current Sublease income recorded as other income Sublease Income 2024 Long-Term Debt, Maturity, Year Three Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Research and development expenses Research and Development Expense [Member] Noncash interest expense Paid-in-Kind Interest Fair Value, Balance Sheet Grouping, Financial Statement Captions Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Accumulated deficit Retained Earnings (Accumulated Deficit) Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Entity Incorporation, State Entity Incorporation, State or Country Code Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Debt discount, net of accretion Debt Instrument, Unamortized Discount 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Restricted cash Restricted Cash, Noncurrent 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Unrecognized compensation costs related to unvested options and unvested restricted stock Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Sale of Stock [Axis] Sale of Stock [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Weighted average common shares outstanding—basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Preferred stock, $0.0001 par value; 25,000,000 shares authorized at March 31, 2021 and December 31, 2020; no shares issued or outstanding Preferred Stock, Value, Issued Total Lease, Cost Total other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Total operating expenses Operating Expenses Agreements [Axis] Agreements [Axis] Agreements. Document Transition Report Document Transition Report Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Marketable securities Marketable Securities Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Share-based Payment Arrangement Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Warrants to purchase common stock Warrant [Member] Other income (expense): Nonoperating Income (Expense) [Abstract] Principal amount of long-term debt Principal borrowing amount Debt Instrument, Face Amount Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Level 2 Fair Value, Inputs, Level 2 [Member] Document Quarterly Report Document Quarterly Report Collaboration revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Oxford Finance LLC Oxford Finance LLC [Member] Oxford finance llc. Measurement Frequency [Domain] Measurement Frequency [Domain] General and administrative expenses General and Administrative Expense [Member] Equity [Abstract] Equity [Abstract] Total Assets, Fair Value Disclosure Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Supplemental disclosure of noncash investing and financing information: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Leasehold improvements landlord allowance to be repaid Leasehold Improvements Landlord Allowance To Be Repaid An additional monetary allowance granted by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenant's occupancy. This additional amount will result in additional rent payments to the landlord. Deferred revenue Contract with Customer, Liability, Current Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Summary of Supplemental Cash Flow Information Related to Leases Schedule Of Supplemental Cash Flow Information Related To Leases [Table Text Block] Tabular disclosure of supplemental information for the statement of cash flows related to leases. Statement [Line Items] Statement [Line Items] Prepayment Period [Axis] Prepayment Period [Axis] Summary of Earnings Per Share Diluted Anti Dilutive Impact Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Forecast Forecast [Member] Class of Stock [Domain] Class of Stock [Domain] Debt instrument, term Debt Instrument, Term Entity File Number Entity File Number Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Period Three Prepayment Period Three [Member] Prepayment Period Three Debt Disclosure [Abstract] Debt Disclosure [Abstract] Weighted-average remaining lease term - operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Statement [Table] Statement [Table] Amount receivable for achievement of milestones Milestone Receivable Upon Achievement The amount of consideration to be received upon achievement of specified milestones. Flagship Pioneering Flagship Pioneering [Member] Flagship Pioneering. Statistical Measurement [Axis] Statistical Measurement [Axis] Leasehold improvements landlord allowance Leasehold Improvements Landlord Allowance The monetary allowance granted by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenant's occupancy. Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Future sublease income outstanding Lessor, Operating Lease, Payments to be Received Unsatisfied portion of the performance obligation Revenue, Remaining Performance Obligation, Amount Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Leasehold improvements Leaseholds and Leasehold Improvements [Member] Stanford Stanford License Agreement [Member] Common stock, $0.0001 par value; 175,000,000 shares authorized at March 31, 2021 and December 31, 2020; 36,826,775 shares issued and outstanding at March 31, 2021; 36,790,946 shares issued and outstanding at December 31, 2020 Common Stock, Value, Issued Net loss per share attributable to common stockholders—basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Document Fiscal Year Focus Document Fiscal Year Focus Entity Small Business Entity Small Business Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Less: Current portion of long-term debt Long-term Debt, Current Maturities Entity Current Reporting Status Entity Current Reporting Status Sale of stock issue price per share (in dollars per share) Sale of Stock, Price Per Share Notes Payable Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Interest income and other income (expense), net Interest Income And Other Income Expense Amount of interest income and income (expense) related to nonoperating activities, classified as other. Retirement Benefits [Abstract] Retirement Benefits [Abstract] 2020 Equity Incentive Plan Two Thousand Twenty Equity Incentive Plan [Member] Amendment Flag Amendment Flag Debt, final payment fee percentage Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid Percentage Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt, as a percentage of the amounts drawn under the Term Loan. Leases Lessee, Finance Leases [Text Block] Number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Marketable Securities and Fair Value Measurements Marketable Securities and Fair Value Measurements [Text Block] The entire disclosure for marketable securities and fair value measurements. Collaboration Agreement Collaborative Arrangement Disclosure [Text Block] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Common stock shares available for grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Other Other Accrued Liabilities, Current Additional borrowing capacity Line Of Credit Additional Borrowing Capacity Line Of Credit Additional Borrowing Capacity Payments made to related party under service agreement Cash Payments Related Party Cash payments made during the period to related parties as part of a service or consulting agreement. Operating lease liability Total operating lease liabilities Total operating lease liabilities Operating Lease, Liability Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Related Party [Domain] Related Party [Domain] Long-term debt, net of current portion Long-term Debt, Excluding Current Maturities Measurement Frequency [Axis] Measurement Frequency [Axis] Related Party Transaction Related Party Transaction [Line Items] Office Space In Cambridge, Massachusetts Office Space In Cambridge, Massachusetts [Member] Office Space In Cambridge, Massachusetts Financial Instruments [Domain] Financial Instruments [Domain] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Finance lease contract term (years) Lessee, Finance Lease, Term of Contract Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Purchases of property and equipment included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Entity Address, City Entity Address, City or Town Accrued employee compensation and benefits Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating lease cost Operating Lease, Cost General and administrative General and Administrative Expense Financial Instrument [Axis] Financial Instrument [Axis] Change in fair value of preferred stock warrant liability Change in fair value of preferred stock warrant liability Fair Value Adjustment of Warrants Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Operating lease term extension (years) Lessee, Operating Lease, Renewal Term Anti-dilutive shares excluded from the calculation of earnings per share (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Ex Transition Period Entity Ex Transition Period Short-term lease cost Short-term Lease, Cost Annual share percentage increase (percent) Share-based Compensation, Annual Share Percentage Increase Share-based Compensation, Annual Share Percentage Increase 2025 Long-Term Debt, Maturity, Year Four Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Equity Component [Domain] Equity Component [Domain] Income Statement Location [Axis] Income Statement Location [Axis] Reimbursements from lessor Payments for (Proceeds from) Tenant Allowance Unrealized losses on marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Entity Tax Identification Number Entity Tax Identification Number Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Warrants exercisable term Warrants and Rights Outstanding, Term Unrealized gains on marketable securities Marketable Securities, Unrealized Gain (Loss) Stock-Based Compensation Share-based Payment Arrangement [Text Block] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Summary of Lease Cost Lease, Cost [Table Text Block] Financing lease liability, net of current portion Finance Lease, Liability, Noncurrent Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Remainder of 2021 (nine months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Warrant fair value Warrants Not Settleable in Cash, Fair Value Disclosure Other assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] LIBOR London Interbank Offered Rate (LIBOR) [Member] Term Loan A Term Loan A [Member] Leases [Abstract] Leases [Abstract] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Vesting of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Accrued tenant improvements Accrued Tenant Improvements Accrued Tenant Improvements Total assets Assets Related Parties Related Party Transactions Disclosure [Text Block] Scenario [Axis] Scenario [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Operating expenses: Operating Expenses [Abstract] Warrants issue price ( per share) Warrants Issue Price Per Share Per unit amount of warrant issued. Title of each class Title of 12(b) Security Finance lease liability Finance Lease, Liability Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Property plant and equipment including finance right of use assets, gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Antidilutive Securities [Axis] Antidilutive Securities [Axis] Prepayment Period [Domain] Prepayment Period [Domain] Prepayment Period [Domain] Nature of Business and Basis of Presentation Business Description and Basis of Presentation [Text Block] Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Class of warrant or right, number of securities called by warrants or rights (shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Document Fiscal Period Focus Document Fiscal Period Focus Interest expense Interest Expense Sale of stock consideration received on the transaction Sale of Stock, Consideration Received on Transaction Depreciation and amortization expense Depreciation, Depletion and Amortization Less: Accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Total liabilities Liabilities Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Additional Office Space In Cambridge, Massachusetts Additional Office Space In Cambridge, Massachusetts [Member] Additional Office Space In Cambridge, Massachusetts Merck Collaboration Agreement Merck Collaboration Agreement [Member] Merck collaboration agreement. Investment Type [Axis] Investment Type [Axis] Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Scientific Founder Scientific Founder [Member] Scientific Founder. Sales based Sales [Member] Term of property subleased under operating lease Lessor, Operating Lease, Term of Contract Weighted average period of unrecognized compensation costs Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Adjustments Scenario, Adjustment [Member] Entity Filer Category Entity Filer Category Summary of Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Noncash lease expense Increase Decrease In Operating Lease Right Of Use Asset Amount of increase (decrease) in right-of-use assets under an operating lease. Common Stock Common Stock [Member] 2023 Long-Term Debt, Maturity, Year Two Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Operating lease rent payments Operating Lease, Expense Summary of Property and Equipment Net Property, Plant and Equipment [Table Text Block] FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasis[Table] Fair Value, Recurring and Nonrecurring [Table] Accounts payable Increase (Decrease) in Accounts Payable U.S. treasury notes US Treasury Securities [Member] Stock issued during the period shares new issues shares (in shares) Stock Issued During Period, Shares, New Issues Debt Instrument [Axis] Debt Instrument [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] U.S. treasury notes (due within one year) US Treasury Notes Securities [Member] Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Money market funds Money Market Funds [Member] Term Loan B Term Loan B [Member] Name of Property [Axis] Name of Property [Axis] Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities Debt, weighted average interest rate Long-term Debt, Weighted Average Interest Rate, over Time Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Issuance of common stock upon exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Related Party Transactions [Abstract] Related Party Transactions [Abstract] Total other income (expense), net Nonoperating Income (Expense) Less: estimated lease incentives Lessee Operating Lease Liability Estimated Lease Incentives Amount of estimated lease incentives used by lessee to determine present value of operating lease payments. Financing lease right-of-use asset Finance Lease, Right-of-Use Asset, after Accumulated Amortization Common stock, shares outstanding (in shares) Beginning balance (Shares) Ending balance (Shares) Common Stock, Shares, Outstanding Summary of Minimum Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Variable lease cost Variable Lease, Cost Stock options to purchase common stock Share-based Payment Arrangement, Option [Member] Basis of presentation Basis of Accounting, Policy [Policy Text Block] Debt instrument, basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Collaboration Agreement [Abstract] Collaboration Agreement [Abstract] Collaboration Agreement Short-term Debt Short-term Debt [Line Items] Research and development Research and Development Expense IPO IPO [Member] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments And Contingencies Thereafter Lessee Operating Lease Liability Payments Due After Year Four Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Agreements [Domain] Agreements [Domain] Agreements. Sale of Stock [Domain] Sale of Stock [Domain] Service agreement term Service agreement term The term of a service agreement in 'PnYnMnDTnHnMnS' format. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Plan Name [Domain] Plan Name [Domain] Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross Upfront payment received from Merck Proceeds From Upfront Payment Proceeds from upfront payment Proceeds from issuance of common stock upon exercise of stock options Proceeds from Stock Options Exercised 2020 Employee Stock Purchase Plan Two Thousand Twenty Employee Stock Purchase Plan [Member] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Prepayment period (months) Prepayment Period Prepayment Period Long-term Debt, Fiscal Year Maturity Long-term Debt, Fiscal Year Maturity [Abstract] Operating lease liabilities arising from obtaining right-of-use assets Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Period One Prepayment Period One [Member] Prepayment Period One Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Organization consolidation and presentation of financial statements. Additional paid-in capital Additional Paid in Capital Class of Stock [Axis] Class of Stock [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Income Statement [Abstract] Income Statement [Abstract] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total cash, cash equivalents and restricted cash shown in the statement of cash flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Period Two Prepayment Period Two [Member] Prepayment Period Two Computer equipment and software Computer equipment and software [Member] Computer equipment and software Summary of Future Long Term Loan Principal Payments Due Schedule of Maturities of Long-term Debt [Table Text Block] Purchases of marketable securities Payments to Acquire Marketable Securities Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Accrued expenses Accrued Liabilities, Current, Total Accrued Liabilities, Current Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Over-Allotment Option Over-Allotment Option [Member] Financing lease liability Finance Lease, Liability, Current Local Phone Number Local Phone Number Name of Property [Domain] Name of Property [Domain] Current assets: Assets, Current [Abstract] Summary of Long Term Debt Schedule of Long-term Debt Instruments [Table Text Block] Entity Address, Street Name Entity Address, Address Line One Deferred revenue Contract with Customer, Liability Entity Emerging Growth Company Entity Emerging Growth Company Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Series A-1, A-2 and B Convertible Preferred Stock Convertible preferred stock (as converted to common stock) Convertible Preferred Stock [Member] Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2022 Long-Term Debt, Maturity, Year One Scenario [Domain] Scenario [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Prepayment fee (percent) Percentage Of Prepayment Fee The fee for prepayment of a loan, as a percentage of the principal amount being prepaid. Maximum Maximum [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Document Period End Date Document Period End Date Restricted cash (current and non-current) Restricted Cash Operating lease liabilities Increase Decrease In Operating Lease Liabilities The increase (decrease) in operating lease liabilities during the reporting period. Accumulated Deficit Retained Earnings [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Property, Plant and Equipment [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Assets not yet placed in service Assets Not Yet Placed In service [Member] Assets Not Yet Placed In service[Member]. Operating lease term (years) Lessee, Operating Lease, Term of Contract Investments [Domain] Investments [Domain] Commitments And Contingencies Commitments And Contingencies [Line Items] Commitments And Contingencies Trading Symbol(s) Trading Symbol Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Remainder of 2021 (nine months) Long-Term Debt, Maturity, Remainder of Fiscal Year Warrants to purchase convertible preferred stock (as converted to common stock) Warrants One [Member] Warrants One Cover [Abstract] Cover [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Laboratory equipment Equipment [Member] Summary of Available for Sale Marketable Securities By Security Type Debt Securities, Available-for-sale [Table Text Block] Current liabilities: Liabilities, Current [Abstract] Entity Shell Company Entity Shell Company Milestones payable upon event Milestones Payable Upon Event The amount the Company will pay for regulatory milestones on each licensed product upon the occurrence of specific events as outlined in the license agreement. Summary of Operating Lease Liabilities Operating Lease Liability [Table Text Block] Tabular disclosure of operating lease liabilities included in the consolidated balance sheet. Recurring Fair Value, Recurring [Member] Recently issued accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 10 fhtx-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 fhtx-20210331_htm.xml IDEA: XBRL DOCUMENT 0001822462 2021-01-01 2021-03-31 0001822462 2021-04-30 0001822462 2021-03-31 0001822462 2020-12-31 0001822462 2020-01-01 2020-03-31 0001822462 us-gaap:ConvertiblePreferredStockMember 2020-12-31 0001822462 us-gaap:CommonStockMember 2020-12-31 0001822462 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001822462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001822462 us-gaap:RetainedEarningsMember 2020-12-31 0001822462 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001822462 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001822462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001822462 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001822462 us-gaap:ConvertiblePreferredStockMember 2021-03-31 0001822462 us-gaap:CommonStockMember 2021-03-31 0001822462 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001822462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001822462 us-gaap:RetainedEarningsMember 2021-03-31 0001822462 us-gaap:ConvertiblePreferredStockMember 2019-12-31 0001822462 us-gaap:CommonStockMember 2019-12-31 0001822462 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001822462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001822462 us-gaap:RetainedEarningsMember 2019-12-31 0001822462 2019-12-31 0001822462 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001822462 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001822462 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001822462 us-gaap:ConvertiblePreferredStockMember 2020-03-31 0001822462 us-gaap:CommonStockMember 2020-03-31 0001822462 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001822462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001822462 us-gaap:RetainedEarningsMember 2020-03-31 0001822462 2020-03-31 0001822462 us-gaap:IPOMember 2020-10-27 2020-10-27 0001822462 us-gaap:IPOMember 2020-10-27 0001822462 us-gaap:OverAllotmentOptionMember 2020-11-19 2020-11-19 0001822462 us-gaap:OverAllotmentOptionMember 2020-11-19 0001822462 2020-07-01 2020-07-31 0001822462 us-gaap:USTreasuryNotesSecuritiesMember 2021-03-31 0001822462 us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001822462 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001822462 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001822462 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001822462 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001822462 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-03-31 0001822462 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-03-31 0001822462 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-03-31 0001822462 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-03-31 0001822462 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001822462 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001822462 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001822462 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001822462 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001822462 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001822462 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001822462 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001822462 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001822462 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001822462 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001822462 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001822462 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001822462 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001822462 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001822462 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001822462 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001822462 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001822462 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001822462 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001822462 us-gaap:EquipmentMember 2021-03-31 0001822462 us-gaap:EquipmentMember 2020-12-31 0001822462 us-gaap:FurnitureAndFixturesMember 2021-03-31 0001822462 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001822462 fhtx:ComputerEquipmentAndSoftwareMember 2021-03-31 0001822462 fhtx:ComputerEquipmentAndSoftwareMember 2020-12-31 0001822462 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2021-03-31 0001822462 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2020-12-31 0001822462 fhtx:AssetsNotYetPlacedInServiceMember 2021-03-31 0001822462 fhtx:AssetsNotYetPlacedInServiceMember 2020-12-31 0001822462 fhtx:TermLoanAMember 2021-03-31 0001822462 fhtx:TermLoanBMember fhtx:OxfordFinanceLlcMember 2020-11-19 0001822462 fhtx:OxfordFinanceLlcMember 2020-11-19 0001822462 fhtx:OxfordFinanceLlcMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-11-19 2020-11-19 0001822462 fhtx:OxfordFinanceLlcMember fhtx:PrepaymentPeriodOneMember 2021-01-01 2021-03-31 0001822462 srt:MaximumMember fhtx:OxfordFinanceLlcMember fhtx:PrepaymentPeriodOneMember 2021-01-01 2021-03-31 0001822462 fhtx:OxfordFinanceLlcMember fhtx:PrepaymentPeriodTwoMember 2021-01-01 2021-03-31 0001822462 srt:MinimumMember fhtx:OxfordFinanceLlcMember fhtx:PrepaymentPeriodTwoMember 2021-01-01 2021-03-31 0001822462 srt:MaximumMember fhtx:OxfordFinanceLlcMember fhtx:PrepaymentPeriodTwoMember 2021-01-01 2021-03-31 0001822462 fhtx:OxfordFinanceLlcMember fhtx:PrepaymentPeriodThreeMember 2021-01-01 2021-03-31 0001822462 srt:MinimumMember fhtx:OxfordFinanceLlcMember fhtx:PrepaymentPeriodThreeMember 2021-01-01 2021-03-31 0001822462 fhtx:OxfordFinanceLlcMember 2021-03-31 0001822462 fhtx:OxfordFinanceLlcMember 2021-01-01 2021-03-31 0001822462 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001822462 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001822462 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001822462 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001822462 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001822462 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001822462 fhtx:WarrantsOneMember 2021-01-01 2021-03-31 0001822462 fhtx:WarrantsOneMember 2020-01-01 2020-03-31 0001822462 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001822462 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0001822462 fhtx:TwoThousandTwentyEquityIncentivePlanMember 2020-10-21 0001822462 fhtx:TwoThousandTwentyEquityIncentivePlanMember 2021-03-31 0001822462 fhtx:TwoThousandTwentyEquityIncentivePlanMember 2021-01-01 2021-01-01 0001822462 fhtx:TwoThousandTwentyEquityIncentivePlanMember 2021-01-01 2021-03-31 0001822462 fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember 2020-10-21 0001822462 fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-03-31 0001822462 fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-01-01 2021-01-01 0001822462 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001822462 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001822462 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001822462 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001822462 srt:MaximumMember fhtx:ResearchDevelopmentAndRegulatoryMember 2021-01-01 2021-03-31 0001822462 srt:MaximumMember us-gaap:SalesMember 2021-01-01 2021-03-31 0001822462 fhtx:MerckCollaborationAgreementMember 2021-01-01 2021-03-31 0001822462 fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember 2019-10-31 0001822462 fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember srt:ScenarioForecastMember 2020-01-01 2027-12-31 0001822462 srt:MaximumMember fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember 2019-10-31 0001822462 fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember 2021-01-01 2021-03-31 0001822462 fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember 2020-01-01 2020-03-31 0001822462 fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember 2020-01-01 0001822462 fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember us-gaap:ScenarioAdjustmentMember 2020-06-29 0001822462 fhtx:OfficeSpaceInCambridgeMassachusettsMember 2020-04-30 0001822462 fhtx:AdditionalOfficeSpaceInCambridgeMassachusettsMember 2021-02-28 0001822462 srt:MaximumMember fhtx:StanfordLicenseAgreementMember 2021-01-01 2021-03-31 0001822462 fhtx:FlagshipPioneeringMember 2015-10-01 2015-10-31 0001822462 fhtx:FlagshipPioneeringMember 2021-01-01 2021-03-31 0001822462 fhtx:FlagshipPioneeringMember 2020-01-01 2020-03-31 0001822462 fhtx:FlagshipPioneeringMember 2021-03-31 0001822462 fhtx:FlagshipPioneeringMember 2020-12-31 0001822462 fhtx:ScientificFounderMember 2015-10-01 2015-10-31 0001822462 fhtx:ScientificFounderMember 2021-01-01 2021-03-31 0001822462 fhtx:ScientificFounderMember 2020-01-01 2020-03-31 shares iso4217:USD iso4217:USD shares pure fhtx:vote utr:sqft false 2021 Q1 0001822462 --12-31 10-Q true 2021-03-31 false 001-39634 Foghorn Therapeutics Inc. DE 47-5271393 500 Technology Square, Ste 700 Cambridge MA 02139 617 586-3100 Common Stock, $0.0001 par value per share FHTX NASDAQ Yes Yes Non-accelerated Filer true true false false 36846084 66449000 92795000 94468000 92975000 4398000 4917000 165315000 190687000 19493000 19528000 1733000 1733000 1603000 842000 41742000 42804000 229886000 255594000 2911000 3680000 5126000 9161000 5783000 3981000 105000 0 2407000 2024000 16332000 18846000 19739000 19654000 56548000 58361000 225000 0 11878000 12546000 104722000 109407000 0.0001 0.0001 25000000 25000000 0 0 0 0 0 0 0.0001 0.0001 175000000 175000000 36826775 36826775 36790946 36790946 4000 4000 311076000 309126000 6000 -7000 -185922000 -162936000 125164000 146187000 229886000 255594000 286000 0 18726000 11503000 4690000 2221000 23416000 13724000 -23130000 -13724000 486000 258000 630000 29000 0 -1000 144000 -228000 -22986000 -13952000 -0.62 -2.71 36817277 5154229 -22986000 -13952000 13000 0 13000 0 -22973000 -13952000 0 0 36790946 4000 309126000 -7000 -162936000 146187000 35829 62000 62000 1888000 1888000 13000 13000 -22986000 -22986000 0 0 36826775 4000 311076000 6000 -185922000 125164000 28615546 86544000 4870851 0 6120000 0 -94136000 -88016000 97034 247000 247000 222973 517000 517000 -13952000 -13952000 28615546 86544000 5190858 0 6884000 0 -108088000 -101204000 -22986000 -13952000 1888000 517000 772000 255000 0 -1000 1062000 608000 85000 64000 13000 0 295000 64000 -754000 969000 -2609000 -17000 -11000 859000 -286000 0 -23147000 -10762000 1794000 1021000 26467000 0 25000000 0 -3261000 -1021000 62000 247000 62000 247000 -26346000 -11536000 94528000 17255000 68182000 5719000 400000 190000 959000 1471000 66449000 3443000 1733000 2276000 68182000 5719000 Nature of Business and Basis of Presentation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foghorn Therapeutics Inc. (the “Company”) is a clinical-stage biopharmaceutical company discovering and developing a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. The Company uses its proprietary Gene Traffic Control platform to identify, validate and potentially drug targets within the system. The Company was founded in October 2015 as a Delaware corporation. The Company is headquartered in Cambridge, Massachusetts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks similar to those of other early-stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, the impact of the COVID-19 pandemic and the need to obtain adequate additional financing to fund the development of its products. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (“COVID-19”) outbreak a pandemic. The Company’s operations have not been significantly impacted by the COVID-19 pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 outbreak on the Company’s financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s results may be materially adversely affected.</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 27, 2020, the Company completed its initial public offering (“IPO”) pursuant to which it issued and sold 7,500,000 shares of its common stock at a public offering price of $16.00 per share, resulting in net proceeds of $108.0 million, after deducting underwriting discounts and commissions and other offering expenses. On November 19, 2020, the Company issued and sold an additional 951,837 shares of common stock at the IPO price of $16.00 per share pursuant to the underwriters’ partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $14.2 million after deducting underwriting discounts and commissions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations primarily with proceeds from sales of preferred stock, debt financing, an upfront payment of $15.0 million the Company received in July 2020 under a collaboration agreement with Merck Sharp &amp; Dohme Corp. (see Note 9), and most recently, with proceeds from the sale of common stock in the IPO completed in October 2020. The Company has incurred losses since inception and as of March 31, 2021, the Company had an accumulated deficit of $185.9 million. The Company expects to continue to generate operating losses in the foreseeable future. As of the issuance date of these interim condensed consolidated financial statements the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will need to obtain additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborative or strategic alliances or licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or programs. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, pipeline expansion or commercialization efforts, which could adversely affect its business prospects. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all.</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated balance sheet as of March 31, 2021, the condensed consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity and cash flows for the three months ended March 31, 2021 and 2020 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2021 and the results of its operations and its cash flows for the three months ended March 31, 2021 and 2020. The results for the three months ended March 31, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period.</span></div> 7500000 16.00 108000000.0 951837 16.00 14200000 15000000.0 -185900000 <div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span></div> Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the Company are set forth in Note 2 to the consolidated financial statements contained in the Company’s 2020 Annual Report on Form 10-K. The Company includes herein certain updates to those policies. </span></div><div style="margin-top:16pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 842, Leases, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renew</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">al or purchase options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company’s policy is to not record leases with an original term of twelve months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company’s existing leases are for office and laboratory space and equipment leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to rent, the leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and liability. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company's financing lease, amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the useful life of the asset or the lease term and is included in operating expenses on the condensed consolidated statements of operations and comprehensive loss. Interest on the finance lease liability is recognized in interest expense on the condensed consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to “opt out” of the extended transition related to complying with new or </span></div>revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. <div style="margin-top:16pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 842, Leases, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renew</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">al or purchase options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company’s policy is to not record leases with an original term of twelve months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company’s existing leases are for office and laboratory space and equipment leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to rent, the leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and liability. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss. </span></div>For the Company's financing lease, amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the useful life of the asset or the lease term and is included in operating expenses on the condensed consolidated statements of operations and comprehensive loss. Interest on the finance lease liability is recognized in interest expense on the condensed consolidated statements of operations and comprehensive loss. <div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to “opt out” of the extended transition related to complying with new or </span></div>revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. Marketable Securities and Fair Value Measurements<div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, available for sale marketable securities by security type consisted of (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"/><td style="width:47.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.058%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes (due within one year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">           Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,463 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,468 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, available for sale marketable securities by security type consisted of (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"/><td style="width:47.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.058%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes (due within one year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,982 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">           Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,982 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,975 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company’s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at March 31, 2021 Using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,423 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,468 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,891 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2020 Using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">           U.S. treasury notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,997 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,997 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">        Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,770 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,972 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,742 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, there were no transfers between Level 1, Level 2 and Level 3.</span></div> <div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, available for sale marketable securities by security type consisted of (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"/><td style="width:47.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.058%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes (due within one year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">           Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,463 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,468 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, available for sale marketable securities by security type consisted of (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"/><td style="width:47.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.058%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes (due within one year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,982 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">           Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,982 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,975 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 94463000 5000 0 94468000 94463000 5000 0 94468000 92982000 0 7000 92975000 92982000 0 7000 92975000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company’s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at March 31, 2021 Using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,423 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,468 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,891 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2020 Using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">           U.S. treasury notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,997 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,997 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">        Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,770 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,972 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,742 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 66423000 0 0 66423000 0 94468000 0 94468000 66423000 94468000 0 160891000 48770000 0 0 48770000 0 42997000 0 42997000 0 92975000 0 92975000 48770000 135972000 0 184742000 Property and Equipment, Net<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:70.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,024 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,961 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets not yet placed in service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,493 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,528 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense, including amortization of financing lease right-of-use assets, was $0.8 million and $0.3 million for the three months ended March 31, 2021 and 2020, respectively.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:70.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,024 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,961 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets not yet placed in service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,493 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,528 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3998000 3740000 815000 815000 100000 100000 17024000 16961000 384000 0 47000 15000 22368000 21631000 2875000 2103000 19493000 19528000 800000 300000 Accrued Expenses<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:70.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.934%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued tenant improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,161 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:70.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.934%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued tenant improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,161 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 978000 3513000 913000 2385000 2477000 2146000 620000 979000 138000 138000 5126000 9161000 Notes Payable<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:70.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Final payment fee</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net of accretion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of discount and current portion</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,739 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,654 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had outstanding loans under its loan and security agreement of $20.0 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2020, the Company entered into a loan and security agreement (the "Oxford Loan Agreement"), with Oxford Finance LLC, or Oxford, for an aggregate principal amount of $20.0 million (the "Oxford Term Loan A") and up to an additional $5.0 million (the "Oxford Term Loan B"). On November 19, 2020, the Company borrowed $20.0 million under the Oxford Term Loan A. The Term Loan bears interest at a floating per annum rate equal to the greater of (i) 8.0% and (ii) the sum of (a) thirty-day LIBOR rate plus (b) 7.84%. In addition, upon loan maturity or prepayment, the Company is required to make a final payment fee equal to 5.0% of the aggregate principal amount borrowed which is being amortized to interest expense over the term of the debt using the effective interest method.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to make monthly interest only payments under the Oxford Loan each month beginning on January 1, 2021. Beginning on December 1, 2023, the Company is required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, based upon a repayment schedule equal to 24 months, with a final maturity date of November 1, 2025 (the “Maturity Date”). At the Company’s option, the Company may elect to prepay the loans subject to a prepayment fee equal to the following percentage of the principal amount being prepaid: 2% if an advance is prepaid during the first 12 months following the applicable advance date, 1% if an advance is prepaid after 12 months but prior to 24 months following the applicable advance date, and 0.5% if an advance is prepaid any time after 24 months following the applicable advance date but prior to the Maturity Date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations under the Oxford Loan Agreement are secured by a security interest in all of its assets, other than its intellectual property. The Company is also subject to certain affirmative and negative covenants restricting the Company’s activities, including limitations on dispositions, mergers or acquisitions; encumbering its intellectual property; incurring indebtedness or liens; paying dividends; making certain investments; and engaging in certain other business transactions. The obligations under the Loan are subject to acceleration upon the occurrence of specified events of default, including a material adverse change in the Company’s business, operations or financial or other condition. Upon the occurrence of an event of default and until such event of default is no longer continuing, the annual interest rate will be 5.0% above the otherwise applicable rate. As of March 31, 2021 and December 31, 2020, the Company believes an event of default would be remote.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Oxford Loan Agreement, the Company granted warrants to purchase 18,445 shares of the Company’s common stock at $16.26 per share. The issued warrants are exercisable for 10 years. The Company valued the warrants using the Black-Scholes option pricing model and determined the fair value of the warrants to be $0.2 million. The Company determined the warrants met the criteria for equity classification, and, as such, the fair value of the warrants were recorded as additional paid-in capital and as a discount to the debt which is being amortized to interest expense over the term of the Oxford Loan of five years. In addition, the Company incurred debt issuance costs of $0.2 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the interest rate applicable to outstanding borrowings under the Oxford Loan Agreement was 8.0%. During the three months ended March 31, 2021, the weighted average effective interest rate on outstanding borrowings was approximately 9.7%.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, future principal payments due are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021 (nine months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2020, the Company had outstanding loans under its amended loan and security agreement with Comerica Bank. In November 2020, the Company used a portion of the proceeds from its new loan and security agreement described above to repay the outstanding principal balances in full plus unpaid accrued interest and the final payment fee.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:70.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Final payment fee</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net of accretion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of discount and current portion</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,739 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,654 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 20000000 20000000 0 0 20000000 20000000 1000000 1000000 1261000 1346000 19739000 19654000 20000000.0 20000000.0 5000000.0 20000000.0 0.080 0.0784 0.050 0.02 P12M 0.01 P12M P24M 0.005 P24M 0.050 18445 16.26 P10Y 200000 P5Y 200000 0.080 0.097 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, future principal payments due are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021 (nine months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 833000 10000000 9167000 20000000 Common Stock and Net Loss Per Share<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents presented based on amounts outstanding at each period end, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,303,254 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785,380 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,467,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase convertible preferred stock<br/>(as converted to common stock)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,321,699 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,936,239 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents presented based on amounts outstanding at each period end, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,303,254 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785,380 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,467,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase convertible preferred stock<br/>(as converted to common stock)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,321,699 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,936,239 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6303254 3785380 18445 0 0 15467863 0 14076 0 668920 6321699 19936239 Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Stock incentive plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s 2016 Stock Incentive Plan, (the “2016 Plan”) provided for the Company to grant incentive stock options or nonqualified stock options and other equity awards to employees, directors and consultants of the Company. Upon the effectiveness of the 2020 Equity Incentive Plan (the “2020 Plan”) in October 2020, the Company ceased granting additional awards under the 2016 Plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2020, the Company’s board of directors adopted and its stockholders approved the 2020 Plan, which became effective on October 21, 2020. The 2020 Plan provides for the grant of incentive stock options, non-qualified options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The number of shares initially reserved for issuance under the 2020 Plan was (i) 2,200,000 shares (the “share pool”), plus (ii) the number of shares of common stock available for issuance under the 2016 Plan as of the effective date of the 2020 Plan, plus the number of shares of common stock underlying awards under the 2016 Plan that on or after the date of adoption expire or become unexercisable without delivery of shares, are forfeited to, or repurchased for cash, are settled in cash, or otherwise become available again for grant under the 2016 Plan, in each case, in accordance with its terms (up to an aggregate of 5,078,295 shares). As of March 31, 2021, 2,380,492 shares remained available for future grant under the 2020 Plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share pool will automatically increase on January 1 of each year from 2021 to 2030 by the lesser of (i) four percent of the number of shares of our common stock outstanding as of the close of business on the immediately preceding December 31 and (ii) the number of shares determined by the board of directors on or prior to such date for such year. The number of shares reserved for issuance under the 2020 Plan was increased by 1,471,576 shares effective January 1, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, or its committee if so delegated. Stock options granted with service-based vesting conditions generally vest over four years and expire after ten years. The exercise price for stock options granted is not less than the fair value of common stock on the date of grant. The Company bases fair value of common stock on the quoted market price. Prior to the IPO, the board of directors determined the value the Company’s common stock, taking into consideration its most recently available valuation of common stock performed by third parties as well as additional relevant factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2020, the Company’s board of directors adopted and its stockholders approved the 2020 Employee Stock Purchase Plan (the “ESPP”), which became effective on October 21, 2020. The aggregate number of shares of common stock available for purchase pursuant to the exercise of options under the ESPP is 360,000 shares, plus an automatic annual increase, as of January 1 of each year from 2021 to 2030, equal to the lesser of one percent of the number of shares of common stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding as of the close of business on the immediately preceding December 31 and (ii) the number of shares determined by the board of directors on or prior to such date for such year (up to a maximum of 3,220,520 shares). The number of shares reserved for issuance under the ESPP was increased by 367,894 shares effective January 1, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, no offering periods have commenced under the ESPP.</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.953%"><tr><td style="width:1.0%"/><td style="width:63.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.336%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, total unrecognized compensation cost related to unvested options was $26.3 million, which is expected to be recognized over a weighted average period of 3.3 years.</span></div> 2200000 5078295 2380492 0.04 1471576 P4Y P10Y 360000 0.01 3220520 367894 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.953%"><tr><td style="width:1.0%"/><td style="width:63.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.336%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1014000 327000 874000 190000 1888000 517000 26300000 P3Y3M18D Collaboration Agreement<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a research collaboration and license agreement (the “Collaboration Agreement”) with Merck Sharp &amp; Dohme Corp. (“Merck”). The Company and Merck will apply Foghorn’s proprietary Gene Traffic Control platform to discover and develop novel therapeutics. Under the Collaboration Agreement, the Company granted Merck exclusive global rights to develop, manufacture and commercialize drugs that target dysregulation of a single transcription factor. Under the terms of the Collaboration Agreement, the Company and Merck are each responsible to perform certain research activities in accordance with a mutually agreed upon research plan. Merck may substitute the selected transcription factor during certain stages of the research program, subject to certain limitations. Following completion of the research program, Merck is responsible for the development and commercialization of the compounds developed pursuant to the research program and any product containing such compounds. Pursuant to the Collaboration Agreement, the Company will also participate on a joint steering committee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Foghorn received a nonrefundable upfront payment of $15.0 million from Merck and is eligible to receive up to $245.0 million upon achievement of specified research, development and regulatory milestones by any product candidate generated by the collaboration, and up to $165.0 million upon achievement of specified sales-based milestones per approved product from the collaboration, if any. The Company will be eligible to receive tiered royalties, calculated on a product-by-product and country-by-country basis, on net sales of approved products from the collaboration, if any, at royalty rates ranging from the mid single digits to low tens, depending on whether the products are covered by patent rights it licenses to Merck.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the Collaboration Agreement will continue in full force and effect until one or more products has received marketing authorization and, thereafter, until expiration of all royalty obligations under the Collaboration Agreement. The Company or Merck may terminate the Collaboration Agreement upon an uncured material breach by the other party or insolvency of the other party. Merck may also terminate the Merck Collaboration Agreement for any reason upon certain notice to the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the (1) research, development, manufacture and commercialization licenses, (2) the research activities performed by the Company and (3) service on the joint committees represent a single performance obligation under the Collaboration Agreement. The Company determined that Merck cannot benefit from the licenses separately from the research activities and participation on the joint steering committee because these services are specialized and rely on the Company’s expertise such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent one combined performance obligation, and the entire transaction price was allocated to that single combined performance obligation. The performance obligation will be satisfied over the research term as the Company performs the research activities and participates in a joint steering committee to oversee research activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront payment of $15.0 million was initially recorded as deferred revenue and is being recognized as revenue as the performance obligation is satisfied. The Company recognizes revenue using the cost-to-cost method, which it believes best depicts the transfer of control to the customer over time. Under the cost-to-cost method, the extent of progress towards </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. As of March 31, 2021, the potential research, development and regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price. Sales-based royalties and milestone payments, which predominantly relate to the license, will be recognized if and when the related sales occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the aggregate amount of the transaction price related to the unsatisfied portion of the performance obligation is $14.3 million, which is expected to be recognized as revenue through 2028. The Company does not expect collaboration revenue to be recognized evenly over this period as it will be recognized on a percentage of completion basis (using cost-to-cost method) as the Company performs the research activities and participates on the joint steering committee, which will likely vary from period to period. In estimating the total costs to satisfy its single performance obligation pursuant to the Collaboration Agreement, the Company is required to make significant estimates including an estimate of the number of transcription factor substitutions and the expected time and expected costs to fulfill the performance obligation. The cumulative effect of revisions to the total estimated costs to complete the Company’s single performance obligation will be recorded in the period in which the changes are identified, and amounts can be reasonably estimated. While such revisions will have no impact on the Company’s cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, the Company assessed the Collaboration Agreement to determine whether a significant financing component exists and concluded that a significant financing component does not exist. For the three months ended March 31, 2021, the Company had recorded $0.3 million of revenue under the Collaboration Agreement, which was included in deferred revenue at the beginning of the period.</span></div> 15000000.0 245000000.0 165000000.0 15000000.0 14300000 300000 Leases<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into a lease for 81,441 square feet of office and laboratory space in Cambridge, Massachusetts, commencing in January 2020 (the “New Lease”). The initial term of the New Lease was eight years with a five-year option to extend at fair-market rent at the time of the extension. The base rent payments escalate annually over the eight-year lease term and totaled approximately $60.3 million. In connection with the New Lease, the landlord agreed to fund up to $3.0 million in tenant improvements to the leased facility as well as up to an additional $16.3 million, which resulted in additional rent payments to the landlord over the lease term. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, $1.5 million and $0.7 million, respectively, of leasehold improvements were reimbursed by the landlord, which resulted in an increase to operating lease liabilities. The Company will be obligated to pay its portion o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f real estate taxes and costs related to the premises, including costs of operations and management of the leased premises. On January 1, 2020, the lease commencement date, the Company recorded an operating lease asset of $38.6 million and corresponding lease liability of $38.3 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company amended the New Lease to defer payment of a portion of the base rent and operating expenses and to extend the lease term by nine months to September 2028. The amendment was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date of June 29, 2020 resulting in an increase of $7.4 million to both the right-of-use asset and lease liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a lease for office and laboratory facilities in Cambridge, Massachusetts under a noncancellable operating lease that began in August 2017 and expired in March 2025. In April 2020, this lease was assigned and assumed by a related party which became effective in October 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.953%"><tr><td style="width:1.0%"/><td style="width:63.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.336%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities arising from obtaining right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,306 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities arising from obtaining right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate as of period ends were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under operating leases as of March 31, 2021 were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021 (nine months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,005 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,355 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,261)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: estimated lease incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,331 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in the condensed consolidated balance sheet (in thousands):</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,783 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,331 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sublease agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into a two-year sublease agreement to sublet approximately 16,843 square feet of office space under the New Lease, as amended, which began in July 2020. In February 2021, the Company entered into an amendment to the sublease to sublet approximately 2,980 square feet of additional office space to the sublessee for the remaining lease term. As of March 31, 2021, the remaining rent payments due to the Company under the amended sublease were $2.6 million. During the three months ended March 31, 2021, the Company recorded other income of $0.6 million related to this sublease. </span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing lease</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n October 2020,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company entered into an equipment lease with a three-year term and an optional purchase option. The Company analyzed the terms of the lease and, due to the likelihood of the Company exercising a purchase option at the end of </span></div>the three-year lease term, classified this lease as a financing lease. On March 31, 2021, the lease commencement date, the Company recorded a financing lease right-of-use asset of $0.4 million, included in property and equipment, net, and a corresponding financing lease liability of $0.3 million on the condensed consolidated balance sheets. See Notes 2 and 4 for additional information. Leases<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into a lease for 81,441 square feet of office and laboratory space in Cambridge, Massachusetts, commencing in January 2020 (the “New Lease”). The initial term of the New Lease was eight years with a five-year option to extend at fair-market rent at the time of the extension. The base rent payments escalate annually over the eight-year lease term and totaled approximately $60.3 million. In connection with the New Lease, the landlord agreed to fund up to $3.0 million in tenant improvements to the leased facility as well as up to an additional $16.3 million, which resulted in additional rent payments to the landlord over the lease term. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, $1.5 million and $0.7 million, respectively, of leasehold improvements were reimbursed by the landlord, which resulted in an increase to operating lease liabilities. The Company will be obligated to pay its portion o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f real estate taxes and costs related to the premises, including costs of operations and management of the leased premises. On January 1, 2020, the lease commencement date, the Company recorded an operating lease asset of $38.6 million and corresponding lease liability of $38.3 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company amended the New Lease to defer payment of a portion of the base rent and operating expenses and to extend the lease term by nine months to September 2028. The amendment was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date of June 29, 2020 resulting in an increase of $7.4 million to both the right-of-use asset and lease liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a lease for office and laboratory facilities in Cambridge, Massachusetts under a noncancellable operating lease that began in August 2017 and expired in March 2025. In April 2020, this lease was assigned and assumed by a related party which became effective in October 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.953%"><tr><td style="width:1.0%"/><td style="width:63.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.336%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities arising from obtaining right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,306 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities arising from obtaining right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate as of period ends were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under operating leases as of March 31, 2021 were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021 (nine months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,005 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,355 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,261)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: estimated lease incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,331 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in the condensed consolidated balance sheet (in thousands):</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,783 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,331 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sublease agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into a two-year sublease agreement to sublet approximately 16,843 square feet of office space under the New Lease, as amended, which began in July 2020. In February 2021, the Company entered into an amendment to the sublease to sublet approximately 2,980 square feet of additional office space to the sublessee for the remaining lease term. As of March 31, 2021, the remaining rent payments due to the Company under the amended sublease were $2.6 million. During the three months ended March 31, 2021, the Company recorded other income of $0.6 million related to this sublease. </span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing lease</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n October 2020,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company entered into an equipment lease with a three-year term and an optional purchase option. The Company analyzed the terms of the lease and, due to the likelihood of the Company exercising a purchase option at the end of </span></div>the three-year lease term, classified this lease as a financing lease. On March 31, 2021, the lease commencement date, the Company recorded a financing lease right-of-use asset of $0.4 million, included in property and equipment, net, and a corresponding financing lease liability of $0.3 million on the condensed consolidated balance sheets. See Notes 2 and 4 for additional information. 81441 P8Y P5Y P8Y 60300000 3000000.0 16300000 -1500000 -700000 38600000 38300000 7400000 7400000 The components of lease expense were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.953%"><tr><td style="width:1.0%"/><td style="width:63.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.336%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 1887000 1258000 0 27000 763000 236000 2650000 1521000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities arising from obtaining right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,306 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities arising from obtaining right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate as of period ends were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 2371000 456000 0 38306000 330000 0 P7Y4M24D P7Y8M12D 0.0535 0.0535 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under operating leases as of March 31, 2021 were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021 (nine months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,005 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,355 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,261)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: estimated lease incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,331 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in the condensed consolidated balance sheet (in thousands):</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,783 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,331 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under operating leases as of March 31, 2021 were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021 (nine months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,005 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,355 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,261)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: estimated lease incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,331 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in the condensed consolidated balance sheet (in thousands):</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,783 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,331 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7391000 10005000 10115000 10355000 10603000 30521000 78990000 14261000 2398000 62331000 5783000 56548000 62331000 P2Y 16843 2980 2600000 600000 P3Y P3Y 400000 300000 Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s commitments under its leases are described in Note 10.</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various exclusive and non-exclusive license agreements for certain technologies. Under the terms of these license agreements, the Company could be required to reimburse the licensors for patent expenses and remit amounts in the low single-digit as sales-based royalties upon the occurrence of specific events as outlined in the corresponding license agreements. The Company is also required to make annual license maintenance fees of less than $0.1 million and pay up to $1.1 million in regulatory milestones on each licensed product upon the occurrence of specific events as outlined in one of the license agreements. None of our product candidates utilize technologies covered by these licenses. </span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in litigation or other legal proceedings. The Company is not currently a party to any material litigation or legal proceedings.</span></div> 100000 1100000 Defined Contribution PlanThe Company has a 401(k) defined contribution plan (the “401(k) Plan”) for its employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits. There was no discretionary match made under the 401(k) Plan as of March 31, 2021. Related Parties<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, the Company entered into a five-year service agreement with Flagship Pioneering (“Flagship”), an affiliate of one of its stockholders, Flagship Venture Funds, to provide general and administrative services to the Company, including certain consulting services and the provision of employee health and dental benefit plans for the Company’s employees. The Company made no cash payments to Flagship for services received under this during the three months ended March 31, 2021. The Company made cash payments to Flagship for services received under this agreement of $0.2 million during the three months ended March 31, 2020. As of March 31, 2021 and December 31, 2020, the Company had no accounts payable to Flagship. This agreement expired in 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, the Company entered into a five-year consulting agreement with a scientific founder of the Company who is also a board member and a shareholder. In October 2020, this agreement was extended to January 1, 2022, with an option to renew. During the three months ended March 31, 2021 and 2020, the Company paid the scientific founder $0.1 million. As of March 31, 2021 and December 31, 2020, the Company had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> accounts payable to this scientific founder.</span></div> P5Y 0 200000 0 0 P5Y 100000 100000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2021
Apr. 30, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2021  
Document Transition Report false  
Entity File Number 001-39634  
Entity Registrant Name Foghorn Therapeutics Inc.  
Entity Incorporation, State DE  
Entity Tax Identification Number 47-5271393  
Entity Address, Street Name 500 Technology Square, Ste 700  
Entity Address, City Cambridge  
Entity Address, State MA  
Entity Address, Postal Zip Code 02139  
City Area Code 617  
Local Phone Number 586-3100  
Title of each class Common Stock, $0.0001 par value per share  
Trading Symbol(s) FHTX  
Name of each exchange on which registered NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   36,846,084
Amendment Flag false  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001822462  
Current Fiscal Year End Date --12-31  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 66,449 $ 92,795
Marketable securities 94,468 92,975
Prepaid expenses and other current assets 4,398 4,917
Total current assets 165,315 190,687
Property and equipment, net 19,493 19,528
Restricted cash 1,733 1,733
Other assets 1,603 842
Operating lease right-of-use assets 41,742 42,804
Total assets 229,886 255,594
Current liabilities:    
Accounts payable 2,911 3,680
Accrued expenses 5,126 9,161
Operating lease liabilities 5,783 3,981
Financing lease liability 105 0
Deferred revenue 2,407 2,024
Total current liabilities 16,332 18,846
Long-term Debt 19,739 19,654
Operating lease liabilities, net of current portion 56,548 58,361
Financing lease liability, net of current portion 225 0
Deferred revenue, net of current portion 11,878 12,546
Total liabilities 104,722 109,407
Commitments and contingencies (Note 11)
Stockholders’ equity:    
Preferred stock, $0.0001 par value; 25,000,000 shares authorized at March 31, 2021 and December 31, 2020; no shares issued or outstanding 0 0
Common stock, $0.0001 par value; 175,000,000 shares authorized at March 31, 2021 and December 31, 2020; 36,826,775 shares issued and outstanding at March 31, 2021; 36,790,946 shares issued and outstanding at December 31, 2020 4 4
Additional paid-in capital 311,076 309,126
Accumulated other comprehensive income (loss) 6 (7)
Accumulated deficit (185,922) (162,936)
Total stockholders’ equity 125,164 146,187
Total liabilities and stockholders’ equity $ 229,886 $ 255,594
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 25,000,000 25,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 175,000,000 175,000,000
Common stock, shares issued (in shares) 36,826,775 36,790,946
Common stock, shares outstanding (in shares) 36,826,775 36,790,946
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements Of Operations And Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income Statement [Abstract]    
Collaboration revenue $ 286 $ 0
Operating expenses:    
Research and development 18,726 11,503
General and administrative 4,690 2,221
Total operating expenses 23,416 13,724
Loss from operations (23,130) (13,724)
Other income (expense):    
Interest expense (486) (258)
Interest income and other income (expense), net 630 29
Change in fair value of preferred stock warrant liability 0 1
Total other income (expense), net 144 (228)
Net loss $ (22,986) $ (13,952)
Net loss per share attributable to common stockholders—basic and diluted (in dollars per share) $ (0.62) $ (2.71)
Weighted average common shares outstanding—basic and diluted (in shares) 36,817,277 5,154,229
Comprehensive loss:    
Net loss $ (22,986) $ (13,952)
Other comprehensive loss:    
Unrealized losses on marketable securities 13 0
Total other comprehensive loss 13 0
Total comprehensive loss $ (22,973) $ (13,952)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Series A-1, A-2 and B Convertible Preferred Stock
Beginning balance at Dec. 31, 2019 $ (88,016) $ 0 $ 6,120 $ 0 $ (94,136) $ 86,544
Beginning balance (Shares) at Dec. 31, 2019   4,870,851       28,615,546
Increase (Decrease) in Stockholders' Equity            
Issuance of common stock upon exercise of stock options 247   247      
Issuance of common stock upon exercise of stock options (in shares)   97,034        
Vesting of restricted stock (in shares)   222,973        
Stock-based compensation expense 517   517      
Net loss (13,952)       (13,952)  
Ending balance at Mar. 31, 2020 (101,204) $ 0 6,884 0 (108,088) $ 86,544
Ending balance (Shares) at Mar. 31, 2020   5,190,858       28,615,546
Beginning balance at Dec. 31, 2020 $ 146,187 $ 4 309,126 (7) (162,936) $ 0
Beginning balance (Shares) at Dec. 31, 2020 36,790,946 36,790,946       0
Increase (Decrease) in Stockholders' Equity            
Issuance of common stock upon exercise of stock options $ 62   62      
Issuance of common stock upon exercise of stock options (in shares)   35,829        
Stock-based compensation expense 1,888   1,888      
Unrealized gains on marketable securities 13     13    
Net loss (22,986)       (22,986)  
Ending balance at Mar. 31, 2021 $ 125,164 $ 4 $ 311,076 $ 6 $ (185,922) $ 0
Ending balance (Shares) at Mar. 31, 2021 36,826,775 36,826,775       0
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net loss $ (22,986) $ (13,952)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 1,888 517
Depreciation and amortization expense 772 255
Change in fair value of preferred stock warrant liability 0 (1)
Noncash lease expense 1,062 608
Noncash interest expense 85 64
Accretion of discount on marketable securities (13) 0
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (295) (64)
Accounts payable (754) 969
Accrued expenses and other current liabilities (2,609) (17)
Operating lease liabilities (11) 859
Deferred revenue (286) 0
Net cash used in operating activities (23,147) (10,762)
Cash flows from investing activities:    
Purchases of property and equipment (1,794) (1,021)
Purchases of marketable securities (26,467) 0
Proceeds from the sale of marketable securities 25,000 0
Net cash used in investing activities (3,261) (1,021)
Cash flows from financing activities:    
Proceeds from issuance of common stock upon exercise of stock options 62 247
Net cash provided by financing activities 62 247
Net decrease in cash, cash equivalents and restricted cash (26,346) (11,536)
Cash, cash equivalents and restricted cash at beginning of period 94,528 17,255
Cash, cash equivalents and restricted cash at end of period 68,182 5,719
Supplemental cash flow information:    
Cash paid for interest 400 190
Supplemental disclosure of noncash investing and financing information:    
Purchases of property and equipment included in accounts payable and accrued expenses $ 959 $ 1,471
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2021
Mar. 31, 2020
Reconciliation of cash, cash equivalents and restricted cash:    
Cash and cash equivalents $ 66,449 $ 3,443
Restricted cash (current and non-current) 1,733 2,276
Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 68,182 $ 5,719
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of Business and Basis of Presentation
 3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business and Basis of Presentation Nature of Business and Basis of Presentation
Foghorn Therapeutics Inc. (the “Company”) is a clinical-stage biopharmaceutical company discovering and developing a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. The Company uses its proprietary Gene Traffic Control platform to identify, validate and potentially drug targets within the system. The Company was founded in October 2015 as a Delaware corporation. The Company is headquartered in Cambridge, Massachusetts.
The Company is subject to risks similar to those of other early-stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, the impact of the COVID-19 pandemic and the need to obtain adequate additional financing to fund the development of its products. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.
In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (“COVID-19”) outbreak a pandemic. The Company’s operations have not been significantly impacted by the COVID-19 pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 outbreak on the Company’s financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s results may be materially adversely affected.
Going concern
On October 27, 2020, the Company completed its initial public offering (“IPO”) pursuant to which it issued and sold 7,500,000 shares of its common stock at a public offering price of $16.00 per share, resulting in net proceeds of $108.0 million, after deducting underwriting discounts and commissions and other offering expenses. On November 19, 2020, the Company issued and sold an additional 951,837 shares of common stock at the IPO price of $16.00 per share pursuant to the underwriters’ partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $14.2 million after deducting underwriting discounts and commissions.
The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations primarily with proceeds from sales of preferred stock, debt financing, an upfront payment of $15.0 million the Company received in July 2020 under a collaboration agreement with Merck Sharp & Dohme Corp. (see Note 9), and most recently, with proceeds from the sale of common stock in the IPO completed in October 2020. The Company has incurred losses since inception and as of March 31, 2021, the Company had an accumulated deficit of $185.9 million. The Company expects to continue to generate operating losses in the foreseeable future. As of the issuance date of these interim condensed consolidated financial statements the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months.
The Company will need to obtain additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborative or strategic alliances or licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or programs. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, pipeline expansion or commercialization efforts, which could adversely affect its business prospects. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all.
Basis of presentation
The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Unaudited interim financial information
The accompanying condensed consolidated balance sheet as of March 31, 2021, the condensed consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity and cash flows for the three months ended March 31, 2021 and 2020 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2021 and the results of its operations and its cash flows for the three months ended March 31, 2021 and 2020. The results for the three months ended March 31, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
The accounting policies of the Company are set forth in Note 2 to the consolidated financial statements contained in the Company’s 2020 Annual Report on Form 10-K. The Company includes herein certain updates to those policies.
Leases

In accordance with ASC 842, Leases, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal or purchase options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company’s policy is to not record leases with an original term of twelve months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company’s existing leases are for office and laboratory space and equipment leases.

In addition to rent, the leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and liability.

Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.

For the Company's financing lease, amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the useful life of the asset or the lease term and is included in operating expenses on the condensed consolidated statements of operations and comprehensive loss. Interest on the finance lease liability is recognized in interest expense on the condensed consolidated statements of operations and comprehensive loss.
Recently issued accounting pronouncements
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to “opt out” of the extended transition related to complying with new or
revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Marketable Securities and Fair Value Measurements
 3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Marketable Securities and Fair Value Measurements Marketable Securities and Fair Value Measurements
As of March 31, 2021, available for sale marketable securities by security type consisted of (in thousands):
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
U.S. treasury notes (due within one year)$94,463 $5 $— $94,468 
           Total$94,463 $5 $— $94,468 
As of December 31, 2020, available for sale marketable securities by security type consisted of (in thousands):
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
U.S. treasury notes (due within one year)$92,982 $— $(7)$92,975 
           Total$92,982 $— $(7)$92,975 
The following tables present the Company’s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):
Fair Value Measurements at March 31, 2021 Using:
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds
$66,423 $— $— $66,423 
Marketable securities:
U.S. treasury notes— 94,468 — 94,468 
Total$66,423 $94,468 $— $160,891 
Fair Value Measurements at December 31, 2020 Using:
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds
$48,770 $— $— $48,770 
           U.S. treasury notes— 42,997 — 42,997 
        Marketable securities:
U.S. treasury notes— 92,975 — 92,975 
   Total$48,770 $135,972 $— $184,742 
During the three months ended March 31, 2021 and 2020, there were no transfers between Level 1, Level 2 and Level 3.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment, Net
 3 Months Ended
Mar. 31, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
March 31, 2021December 31, 2020
Laboratory equipment$3,998 $3,740 
Furniture and fixtures815 815 
Computer equipment and software100 100 
Leasehold improvements17,024 16,961 
Financing lease right-of-use asset384 — 
Assets not yet placed in service47 15 
22,368 21,631 
Less: Accumulated depreciation and amortization(2,875)(2,103)
19,493 19,528 
Depreciation and amortization expense, including amortization of financing lease right-of-use assets, was $0.8 million and $0.3 million for the three months ended March 31, 2021 and 2020, respectively.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses
 3 Months Ended
Mar. 31, 2021
Payables and Accruals [Abstract]  
Accrued Expenses Accrued Expenses
Accrued expenses consisted of the following (in thousands):
March 31, 2021December 31, 2020
Accrued employee compensation and benefits$978 $3,513 
Accrued tenant improvements913 2,385 
Accrued external research and development expenses2,477 2,146 
Accrued professional fees620 979 
Other138 138 
$5,126 $9,161 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Notes Payable
 3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Notes Payable Notes Payable
Long-term debt consisted of the following (in thousands):
March 31, 2021December 31, 2020
Principal amount of long-term debt$20,000 $20,000 
Less: Current portion of long-term debt
— — 
Long-term debt, net of current portion20,000 20,000 
Final payment fee
1,000 1,000 
Debt discount, net of accretion
(1,261)(1,346)
Long-term debt, net of discount and current portion$19,739 $19,654 
As of March 31, 2021, the Company had outstanding loans under its loan and security agreement of $20.0 million.
On November 19, 2020, the Company entered into a loan and security agreement (the "Oxford Loan Agreement"), with Oxford Finance LLC, or Oxford, for an aggregate principal amount of $20.0 million (the "Oxford Term Loan A") and up to an additional $5.0 million (the "Oxford Term Loan B"). On November 19, 2020, the Company borrowed $20.0 million under the Oxford Term Loan A. The Term Loan bears interest at a floating per annum rate equal to the greater of (i) 8.0% and (ii) the sum of (a) thirty-day LIBOR rate plus (b) 7.84%. In addition, upon loan maturity or prepayment, the Company is required to make a final payment fee equal to 5.0% of the aggregate principal amount borrowed which is being amortized to interest expense over the term of the debt using the effective interest method.
The Company is required to make monthly interest only payments under the Oxford Loan each month beginning on January 1, 2021. Beginning on December 1, 2023, the Company is required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, based upon a repayment schedule equal to 24 months, with a final maturity date of November 1, 2025 (the “Maturity Date”). At the Company’s option, the Company may elect to prepay the loans subject to a prepayment fee equal to the following percentage of the principal amount being prepaid: 2% if an advance is prepaid during the first 12 months following the applicable advance date, 1% if an advance is prepaid after 12 months but prior to 24 months following the applicable advance date, and 0.5% if an advance is prepaid any time after 24 months following the applicable advance date but prior to the Maturity Date.
The Company's obligations under the Oxford Loan Agreement are secured by a security interest in all of its assets, other than its intellectual property. The Company is also subject to certain affirmative and negative covenants restricting the Company’s activities, including limitations on dispositions, mergers or acquisitions; encumbering its intellectual property; incurring indebtedness or liens; paying dividends; making certain investments; and engaging in certain other business transactions. The obligations under the Loan are subject to acceleration upon the occurrence of specified events of default, including a material adverse change in the Company’s business, operations or financial or other condition. Upon the occurrence of an event of default and until such event of default is no longer continuing, the annual interest rate will be 5.0% above the otherwise applicable rate. As of March 31, 2021 and December 31, 2020, the Company believes an event of default would be remote.
In connection with the Oxford Loan Agreement, the Company granted warrants to purchase 18,445 shares of the Company’s common stock at $16.26 per share. The issued warrants are exercisable for 10 years. The Company valued the warrants using the Black-Scholes option pricing model and determined the fair value of the warrants to be $0.2 million. The Company determined the warrants met the criteria for equity classification, and, as such, the fair value of the warrants were recorded as additional paid-in capital and as a discount to the debt which is being amortized to interest expense over the term of the Oxford Loan of five years. In addition, the Company incurred debt issuance costs of $0.2 million.
As of March 31, 2021, the interest rate applicable to outstanding borrowings under the Oxford Loan Agreement was 8.0%. During the three months ended March 31, 2021, the weighted average effective interest rate on outstanding borrowings was approximately 9.7%.
As of March 31, 2021, future principal payments due are as follows (in thousands):
Remainder of 2021 (nine months)$— 
2022— 
2023833 
202410,000 
2025$9,167 
$20,000 
As of March 31, 2020, the Company had outstanding loans under its amended loan and security agreement with Comerica Bank. In November 2020, the Company used a portion of the proceeds from its new loan and security agreement described above to repay the outstanding principal balances in full plus unpaid accrued interest and the final payment fee.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Common Stock and Net Loss Per Share
 3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Common Stock and Net Loss Per Share Common Stock and Net Loss Per Share
Common Stock
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.
Net Loss Per Share
The following common stock equivalents presented based on amounts outstanding at each period end, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:
March 31,
20212020
Stock options to purchase common stock6,303,254 3,785,380 
Warrants to purchase common stock18,445 — 
Convertible preferred stock (as converted to common stock)— 15,467,863 
Warrants to purchase convertible preferred stock
(as converted to common stock)		— 14,076 
Unvested restricted common stock— 668,920 
6,321,699 19,936,239 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation
 3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
2016 Stock incentive plan
The Company’s 2016 Stock Incentive Plan, (the “2016 Plan”) provided for the Company to grant incentive stock options or nonqualified stock options and other equity awards to employees, directors and consultants of the Company. Upon the effectiveness of the 2020 Equity Incentive Plan (the “2020 Plan”) in October 2020, the Company ceased granting additional awards under the 2016 Plan.
2020 Equity Incentive Plan
On October 21, 2020, the Company’s board of directors adopted and its stockholders approved the 2020 Plan, which became effective on October 21, 2020. The 2020 Plan provides for the grant of incentive stock options, non-qualified options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The number of shares initially reserved for issuance under the 2020 Plan was (i) 2,200,000 shares (the “share pool”), plus (ii) the number of shares of common stock available for issuance under the 2016 Plan as of the effective date of the 2020 Plan, plus the number of shares of common stock underlying awards under the 2016 Plan that on or after the date of adoption expire or become unexercisable without delivery of shares, are forfeited to, or repurchased for cash, are settled in cash, or otherwise become available again for grant under the 2016 Plan, in each case, in accordance with its terms (up to an aggregate of 5,078,295 shares). As of March 31, 2021, 2,380,492 shares remained available for future grant under the 2020 Plan.
The share pool will automatically increase on January 1 of each year from 2021 to 2030 by the lesser of (i) four percent of the number of shares of our common stock outstanding as of the close of business on the immediately preceding December 31 and (ii) the number of shares determined by the board of directors on or prior to such date for such year. The number of shares reserved for issuance under the 2020 Plan was increased by 1,471,576 shares effective January 1, 2021.
The 2020 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, or its committee if so delegated. Stock options granted with service-based vesting conditions generally vest over four years and expire after ten years. The exercise price for stock options granted is not less than the fair value of common stock on the date of grant. The Company bases fair value of common stock on the quoted market price. Prior to the IPO, the board of directors determined the value the Company’s common stock, taking into consideration its most recently available valuation of common stock performed by third parties as well as additional relevant factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant.
2020 Employee Stock Purchase Plan
On October 21, 2020, the Company’s board of directors adopted and its stockholders approved the 2020 Employee Stock Purchase Plan (the “ESPP”), which became effective on October 21, 2020. The aggregate number of shares of common stock available for purchase pursuant to the exercise of options under the ESPP is 360,000 shares, plus an automatic annual increase, as of January 1 of each year from 2021 to 2030, equal to the lesser of one percent of the number of shares of common stock
outstanding as of the close of business on the immediately preceding December 31 and (ii) the number of shares determined by the board of directors on or prior to such date for such year (up to a maximum of 3,220,520 shares). The number of shares reserved for issuance under the ESPP was increased by 367,894 shares effective January 1, 2021.
As of March 31, 2021, no offering periods have commenced under the ESPP.
Stock-based compensation
Stock-based compensation expense was classified in the statements of operations and comprehensive loss as follows (in thousands):
Three Months Ended March 31,
20212020
Research and development expenses$1,014 $327 
General and administrative expenses874 190 
$1,888 $517 
As of March 31, 2021, total unrecognized compensation cost related to unvested options was $26.3 million, which is expected to be recognized over a weighted average period of 3.3 years.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreement
 3 Months Ended
Mar. 31, 2021
Collaboration Agreement [Abstract]  
Collaboration Agreement Collaboration Agreement
In July 2020, the Company entered into a research collaboration and license agreement (the “Collaboration Agreement”) with Merck Sharp & Dohme Corp. (“Merck”). The Company and Merck will apply Foghorn’s proprietary Gene Traffic Control platform to discover and develop novel therapeutics. Under the Collaboration Agreement, the Company granted Merck exclusive global rights to develop, manufacture and commercialize drugs that target dysregulation of a single transcription factor. Under the terms of the Collaboration Agreement, the Company and Merck are each responsible to perform certain research activities in accordance with a mutually agreed upon research plan. Merck may substitute the selected transcription factor during certain stages of the research program, subject to certain limitations. Following completion of the research program, Merck is responsible for the development and commercialization of the compounds developed pursuant to the research program and any product containing such compounds. Pursuant to the Collaboration Agreement, the Company will also participate on a joint steering committee.
Under the terms of the agreement, Foghorn received a nonrefundable upfront payment of $15.0 million from Merck and is eligible to receive up to $245.0 million upon achievement of specified research, development and regulatory milestones by any product candidate generated by the collaboration, and up to $165.0 million upon achievement of specified sales-based milestones per approved product from the collaboration, if any. The Company will be eligible to receive tiered royalties, calculated on a product-by-product and country-by-country basis, on net sales of approved products from the collaboration, if any, at royalty rates ranging from the mid single digits to low tens, depending on whether the products are covered by patent rights it licenses to Merck.
Unless terminated earlier, the Collaboration Agreement will continue in full force and effect until one or more products has received marketing authorization and, thereafter, until expiration of all royalty obligations under the Collaboration Agreement. The Company or Merck may terminate the Collaboration Agreement upon an uncured material breach by the other party or insolvency of the other party. Merck may also terminate the Merck Collaboration Agreement for any reason upon certain notice to the Company.
The Company determined that the (1) research, development, manufacture and commercialization licenses, (2) the research activities performed by the Company and (3) service on the joint committees represent a single performance obligation under the Collaboration Agreement. The Company determined that Merck cannot benefit from the licenses separately from the research activities and participation on the joint steering committee because these services are specialized and rely on the Company’s expertise such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent one combined performance obligation, and the entire transaction price was allocated to that single combined performance obligation. The performance obligation will be satisfied over the research term as the Company performs the research activities and participates in a joint steering committee to oversee research activities.
The upfront payment of $15.0 million was initially recorded as deferred revenue and is being recognized as revenue as the performance obligation is satisfied. The Company recognizes revenue using the cost-to-cost method, which it believes best depicts the transfer of control to the customer over time. Under the cost-to-cost method, the extent of progress towards
completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. As of March 31, 2021, the potential research, development and regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price. Sales-based royalties and milestone payments, which predominantly relate to the license, will be recognized if and when the related sales occur.
As of March 31, 2021, the aggregate amount of the transaction price related to the unsatisfied portion of the performance obligation is $14.3 million, which is expected to be recognized as revenue through 2028. The Company does not expect collaboration revenue to be recognized evenly over this period as it will be recognized on a percentage of completion basis (using cost-to-cost method) as the Company performs the research activities and participates on the joint steering committee, which will likely vary from period to period. In estimating the total costs to satisfy its single performance obligation pursuant to the Collaboration Agreement, the Company is required to make significant estimates including an estimate of the number of transcription factor substitutions and the expected time and expected costs to fulfill the performance obligation. The cumulative effect of revisions to the total estimated costs to complete the Company’s single performance obligation will be recorded in the period in which the changes are identified, and amounts can be reasonably estimated. While such revisions will have no impact on the Company’s cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.
At inception, the Company assessed the Collaboration Agreement to determine whether a significant financing component exists and concluded that a significant financing component does not exist. For the three months ended March 31, 2021, the Company had recorded $0.3 million of revenue under the Collaboration Agreement, which was included in deferred revenue at the beginning of the period.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Leases
 3 Months Ended
Mar. 31, 2021
Leases [Abstract]  
Leases Leases
In October 2019, the Company entered into a lease for 81,441 square feet of office and laboratory space in Cambridge, Massachusetts, commencing in January 2020 (the “New Lease”). The initial term of the New Lease was eight years with a five-year option to extend at fair-market rent at the time of the extension. The base rent payments escalate annually over the eight-year lease term and totaled approximately $60.3 million. In connection with the New Lease, the landlord agreed to fund up to $3.0 million in tenant improvements to the leased facility as well as up to an additional $16.3 million, which resulted in additional rent payments to the landlord over the lease term. During the three months ended March 31, 2021 and 2020, $1.5 million and $0.7 million, respectively, of leasehold improvements were reimbursed by the landlord, which resulted in an increase to operating lease liabilities. The Company will be obligated to pay its portion of real estate taxes and costs related to the premises, including costs of operations and management of the leased premises. On January 1, 2020, the lease commencement date, the Company recorded an operating lease asset of $38.6 million and corresponding lease liability of $38.3 million.
In June 2020, the Company amended the New Lease to defer payment of a portion of the base rent and operating expenses and to extend the lease term by nine months to September 2028. The amendment was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date of June 29, 2020 resulting in an increase of $7.4 million to both the right-of-use asset and lease liabilities.
The Company had a lease for office and laboratory facilities in Cambridge, Massachusetts under a noncancellable operating lease that began in August 2017 and expired in March 2025. In April 2020, this lease was assigned and assumed by a related party which became effective in October 2020.
The components of lease expense were as follows (in thousands):
Three Months Ended March 31,
20212020
Operating lease cost$1,887 $1,258 
Short-term lease cost— 27 
Variable lease cost763 236 
$2,650 $1,521 
Supplemental disclosure of cash flow information related to leases was as follows (in thousands):
Three Months Ended March 31,
20212020
Cash paid for amounts included in the measurement of operating lease liabilities$2,371 $456 
Operating lease liabilities arising from obtaining right-of-use assets$— $38,306 
Financing lease liabilities arising from obtaining right-of-use assets$330 $— 
The weighted-average remaining lease term and discount rate as of period ends were as follows:
March 31, 2021December 31, 2020
Weighted-average remaining lease term - operating leases (in years)7.47.7
Weighted-average discount rate - operating leases5.35 %5.35 %
Future annual minimum lease payments under operating leases as of March 31, 2021 were as follows (in thousands):
Remainder of 2021 (nine months)$7,391 
202210,005 
202310,115 
202410,355 
202510,603 
Thereafter30,521 
Total future minimum lease payments
78,990 
Less: imputed interest(14,261)
Less: estimated lease incentives(2,398)
Total operating lease liabilities
$62,331 
Included in the condensed consolidated balance sheet (in thousands):March 31, 2021
Current operating lease liabilities$5,783 
Operating lease liabilities, net of current portion56,548 
Total operating lease liabilities
$62,331 
Sublease agreement
In April 2020, the Company entered into a two-year sublease agreement to sublet approximately 16,843 square feet of office space under the New Lease, as amended, which began in July 2020. In February 2021, the Company entered into an amendment to the sublease to sublet approximately 2,980 square feet of additional office space to the sublessee for the remaining lease term. As of March 31, 2021, the remaining rent payments due to the Company under the amended sublease were $2.6 million. During the three months ended March 31, 2021, the Company recorded other income of $0.6 million related to this sublease.
Financing lease
In October 2020, the Company entered into an equipment lease with a three-year term and an optional purchase option. The Company analyzed the terms of the lease and, due to the likelihood of the Company exercising a purchase option at the end of
the three-year lease term, classified this lease as a financing lease. On March 31, 2021, the lease commencement date, the Company recorded a financing lease right-of-use asset of $0.4 million, included in property and equipment, net, and a corresponding financing lease liability of $0.3 million on the condensed consolidated balance sheets. See Notes 2 and 4 for additional information.
Leases Leases
In October 2019, the Company entered into a lease for 81,441 square feet of office and laboratory space in Cambridge, Massachusetts, commencing in January 2020 (the “New Lease”). The initial term of the New Lease was eight years with a five-year option to extend at fair-market rent at the time of the extension. The base rent payments escalate annually over the eight-year lease term and totaled approximately $60.3 million. In connection with the New Lease, the landlord agreed to fund up to $3.0 million in tenant improvements to the leased facility as well as up to an additional $16.3 million, which resulted in additional rent payments to the landlord over the lease term. During the three months ended March 31, 2021 and 2020, $1.5 million and $0.7 million, respectively, of leasehold improvements were reimbursed by the landlord, which resulted in an increase to operating lease liabilities. The Company will be obligated to pay its portion of real estate taxes and costs related to the premises, including costs of operations and management of the leased premises. On January 1, 2020, the lease commencement date, the Company recorded an operating lease asset of $38.6 million and corresponding lease liability of $38.3 million.
In June 2020, the Company amended the New Lease to defer payment of a portion of the base rent and operating expenses and to extend the lease term by nine months to September 2028. The amendment was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date of June 29, 2020 resulting in an increase of $7.4 million to both the right-of-use asset and lease liabilities.
The Company had a lease for office and laboratory facilities in Cambridge, Massachusetts under a noncancellable operating lease that began in August 2017 and expired in March 2025. In April 2020, this lease was assigned and assumed by a related party which became effective in October 2020.
The components of lease expense were as follows (in thousands):
Three Months Ended March 31,
20212020
Operating lease cost$1,887 $1,258 
Short-term lease cost— 27 
Variable lease cost763 236 
$2,650 $1,521 
Supplemental disclosure of cash flow information related to leases was as follows (in thousands):
Three Months Ended March 31,
20212020
Cash paid for amounts included in the measurement of operating lease liabilities$2,371 $456 
Operating lease liabilities arising from obtaining right-of-use assets$— $38,306 
Financing lease liabilities arising from obtaining right-of-use assets$330 $— 
The weighted-average remaining lease term and discount rate as of period ends were as follows:
March 31, 2021December 31, 2020
Weighted-average remaining lease term - operating leases (in years)7.47.7
Weighted-average discount rate - operating leases5.35 %5.35 %
Future annual minimum lease payments under operating leases as of March 31, 2021 were as follows (in thousands):
Remainder of 2021 (nine months)$7,391 
202210,005 
202310,115 
202410,355 
202510,603 
Thereafter30,521 
Total future minimum lease payments
78,990 
Less: imputed interest(14,261)
Less: estimated lease incentives(2,398)
Total operating lease liabilities
$62,331 
Included in the condensed consolidated balance sheet (in thousands):March 31, 2021
Current operating lease liabilities$5,783 
Operating lease liabilities, net of current portion56,548 
Total operating lease liabilities
$62,331 
Sublease agreement
In April 2020, the Company entered into a two-year sublease agreement to sublet approximately 16,843 square feet of office space under the New Lease, as amended, which began in July 2020. In February 2021, the Company entered into an amendment to the sublease to sublet approximately 2,980 square feet of additional office space to the sublessee for the remaining lease term. As of March 31, 2021, the remaining rent payments due to the Company under the amended sublease were $2.6 million. During the three months ended March 31, 2021, the Company recorded other income of $0.6 million related to this sublease.
Financing lease
In October 2020, the Company entered into an equipment lease with a three-year term and an optional purchase option. The Company analyzed the terms of the lease and, due to the likelihood of the Company exercising a purchase option at the end of
the three-year lease term, classified this lease as a financing lease. On March 31, 2021, the lease commencement date, the Company recorded a financing lease right-of-use asset of $0.4 million, included in property and equipment, net, and a corresponding financing lease liability of $0.3 million on the condensed consolidated balance sheets. See Notes 2 and 4 for additional information.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Leases
The Company’s commitments under its leases are described in Note 10.
License agreements
The Company has entered into various exclusive and non-exclusive license agreements for certain technologies. Under the terms of these license agreements, the Company could be required to reimburse the licensors for patent expenses and remit amounts in the low single-digit as sales-based royalties upon the occurrence of specific events as outlined in the corresponding license agreements. The Company is also required to make annual license maintenance fees of less than $0.1 million and pay up to $1.1 million in regulatory milestones on each licensed product upon the occurrence of specific events as outlined in one of the license agreements. None of our product candidates utilize technologies covered by these licenses.
Indemnification agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.
Legal Proceedings
From time to time, the Company may become involved in litigation or other legal proceedings. The Company is not currently a party to any material litigation or legal proceedings.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Defined Contribution Plan
 3 Months Ended
Mar. 31, 2021
Retirement Benefits [Abstract]  
Defined Contribution Plan Defined Contribution PlanThe Company has a 401(k) defined contribution plan (the “401(k) Plan”) for its employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits. There was no discretionary match made under the 401(k) Plan as of March 31, 2021.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Related Parties
 3 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
Related Parties Related Parties
In October 2015, the Company entered into a five-year service agreement with Flagship Pioneering (“Flagship”), an affiliate of one of its stockholders, Flagship Venture Funds, to provide general and administrative services to the Company, including certain consulting services and the provision of employee health and dental benefit plans for the Company’s employees. The Company made no cash payments to Flagship for services received under this during the three months ended March 31, 2021. The Company made cash payments to Flagship for services received under this agreement of $0.2 million during the three months ended March 31, 2020. As of March 31, 2021 and December 31, 2020, the Company had no accounts payable to Flagship. This agreement expired in 2020.
In October 2015, the Company entered into a five-year consulting agreement with a scientific founder of the Company who is also a board member and a shareholder. In October 2020, this agreement was extended to January 1, 2022, with an option to renew. During the three months ended March 31, 2021 and 2020, the Company paid the scientific founder $0.1 million. As of March 31, 2021 and December 31, 2020, the Company had de minimis accounts payable to this scientific founder.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Basis of presentation
Basis of presentation
The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Leases
Leases

In accordance with ASC 842, Leases, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal or purchase options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company’s policy is to not record leases with an original term of twelve months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company’s existing leases are for office and laboratory space and equipment leases.

In addition to rent, the leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and liability.

Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.
For the Company's financing lease, amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the useful life of the asset or the lease term and is included in operating expenses on the condensed consolidated statements of operations and comprehensive loss. Interest on the finance lease liability is recognized in interest expense on the condensed consolidated statements of operations and comprehensive loss.
Recently issued accounting pronouncements
Recently issued accounting pronouncements
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to “opt out” of the extended transition related to complying with new or
revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Marketable Securities and Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Summary of Available for Sale Marketable Securities By Security Type
As of March 31, 2021, available for sale marketable securities by security type consisted of (in thousands):
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
U.S. treasury notes (due within one year)$94,463 $5 $— $94,468 
           Total$94,463 $5 $— $94,468 
As of December 31, 2020, available for sale marketable securities by security type consisted of (in thousands):
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
U.S. treasury notes (due within one year)$92,982 $— $(7)$92,975 
           Total$92,982 $— $(7)$92,975 
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables present the Company’s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):
Fair Value Measurements at March 31, 2021 Using:
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds
$66,423 $— $— $66,423 
Marketable securities:
U.S. treasury notes— 94,468 — 94,468 
Total$66,423 $94,468 $— $160,891 
Fair Value Measurements at December 31, 2020 Using:
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market funds
$48,770 $— $— $48,770 
           U.S. treasury notes— 42,997 — 42,997 
        Marketable securities:
U.S. treasury notes— 92,975 — 92,975 
   Total$48,770 $135,972 $— $184,742 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment, Net (Tables)
 3 Months Ended
Mar. 31, 2021
Property, Plant and Equipment [Abstract]  
Summary of Property and Equipment Net
Property and equipment, net consisted of the following (in thousands):
March 31, 2021December 31, 2020
Laboratory equipment$3,998 $3,740 
Furniture and fixtures815 815 
Computer equipment and software100 100 
Leasehold improvements17,024 16,961 
Financing lease right-of-use asset384 — 
Assets not yet placed in service47 15 
22,368 21,631 
Less: Accumulated depreciation and amortization(2,875)(2,103)
19,493 19,528 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses (Tables)
 3 Months Ended
Mar. 31, 2021
Payables and Accruals [Abstract]  
Accrued Expenses
Accrued expenses consisted of the following (in thousands):
March 31, 2021December 31, 2020
Accrued employee compensation and benefits$978 $3,513 
Accrued tenant improvements913 2,385 
Accrued external research and development expenses2,477 2,146 
Accrued professional fees620 979 
Other138 138 
$5,126 $9,161 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Notes Payable (Tables)
 3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Summary of Long Term Debt
Long-term debt consisted of the following (in thousands):
March 31, 2021December 31, 2020
Principal amount of long-term debt$20,000 $20,000 
Less: Current portion of long-term debt
— — 
Long-term debt, net of current portion20,000 20,000 
Final payment fee
1,000 1,000 
Debt discount, net of accretion
(1,261)(1,346)
Long-term debt, net of discount and current portion$19,739 $19,654 
Summary of Future Long Term Loan Principal Payments Due
As of March 31, 2021, future principal payments due are as follows (in thousands):
Remainder of 2021 (nine months)$— 
2022— 
2023833 
202410,000 
2025$9,167 
$20,000 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Common Stock and Net Loss Per Share (Tables)
 3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Summary of Earnings Per Share Diluted Anti Dilutive Impact
The following common stock equivalents presented based on amounts outstanding at each period end, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:
March 31,
20212020
Stock options to purchase common stock6,303,254 3,785,380 
Warrants to purchase common stock18,445 — 
Convertible preferred stock (as converted to common stock)— 15,467,863 
Warrants to purchase convertible preferred stock
(as converted to common stock)		— 14,076 
Unvested restricted common stock— 668,920 
6,321,699 19,936,239 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Summary of Stock-Based Compensation Expense
Stock-based compensation expense was classified in the statements of operations and comprehensive loss as follows (in thousands):
Three Months Ended March 31,
20212020
Research and development expenses$1,014 $327 
General and administrative expenses874 190 
$1,888 $517 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Leases (Tables)
 3 Months Ended
Mar. 31, 2021
Leases [Abstract]  
Summary of Lease Cost The components of lease expense were as follows (in thousands):
Three Months Ended March 31,
20212020
Operating lease cost$1,887 $1,258 
Short-term lease cost— 27 
Variable lease cost763 236 
$2,650 $1,521 
Summary of Supplemental Cash Flow Information Related to Leases
Supplemental disclosure of cash flow information related to leases was as follows (in thousands):
Three Months Ended March 31,
20212020
Cash paid for amounts included in the measurement of operating lease liabilities$2,371 $456 
Operating lease liabilities arising from obtaining right-of-use assets$— $38,306 
Financing lease liabilities arising from obtaining right-of-use assets$330 $— 
The weighted-average remaining lease term and discount rate as of period ends were as follows:
March 31, 2021December 31, 2020
Weighted-average remaining lease term - operating leases (in years)7.47.7
Weighted-average discount rate - operating leases5.35 %5.35 %
Summary of Minimum Lease Payments
Future annual minimum lease payments under operating leases as of March 31, 2021 were as follows (in thousands):
Remainder of 2021 (nine months)$7,391 
202210,005 
202310,115 
202410,355 
202510,603 
Thereafter30,521 
Total future minimum lease payments
78,990 
Less: imputed interest(14,261)
Less: estimated lease incentives(2,398)
Total operating lease liabilities
$62,331 
Included in the condensed consolidated balance sheet (in thousands):March 31, 2021
Current operating lease liabilities$5,783 
Operating lease liabilities, net of current portion56,548 
Total operating lease liabilities
$62,331 
Summary of Operating Lease Liabilities
Future annual minimum lease payments under operating leases as of March 31, 2021 were as follows (in thousands):
Remainder of 2021 (nine months)$7,391 
202210,005 
202310,115 
202410,355 
202510,603 
Thereafter30,521 
Total future minimum lease payments
78,990 
Less: imputed interest(14,261)
Less: estimated lease incentives(2,398)
Total operating lease liabilities
$62,331 
Included in the condensed consolidated balance sheet (in thousands):March 31, 2021
Current operating lease liabilities$5,783 
Operating lease liabilities, net of current portion56,548 
Total operating lease liabilities
$62,331 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of Business and Basis of Presentation (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Nov. 19, 2020
Oct. 27, 2020
Jul. 31, 2020
Mar. 31, 2021
Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements          
Upfront payment received from Merck     $ 15,000 $ 15,000  
Accumulated deficit       $ (185,922) $ (162,936)
IPO          
Organization Consolidation And Presentation Of Financial Statements          
Stock issued during the period shares new issues shares (in shares)   7,500,000      
Sale of stock issue price per share (in dollars per share)   $ 16.00      
Sale of stock consideration received on the transaction   $ 108,000      
Over-Allotment Option          
Organization Consolidation And Presentation Of Financial Statements          
Stock issued during the period shares new issues shares (in shares) 951,837        
Sale of stock issue price per share (in dollars per share) $ 16.00        
Sale of stock consideration received on the transaction $ 14,200        
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Marketable Securities and Fair Value Measurements - Summary of Available for Sale Marketable Securities By Security Type (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions    
Amortized Cost $ 94,463 $ 92,982
Gross Unrealized Gains 5 0
Gross Unrealized Losses 0 (7)
Estimated Fair Value 94,468 92,975
U.S. treasury notes (due within one year)    
Fair Value, Balance Sheet Grouping, Financial Statement Captions    
Amortized Cost 94,463 92,982
Gross Unrealized Gains 5 0
Gross Unrealized Losses 0 (7)
Estimated Fair Value $ 94,468 $ 92,975
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Marketable Securities and Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Marketable securities $ 94,468 $ 92,975
Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Total 160,891 184,742
Recurring | U.S. treasury notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Marketable securities 94,468 92,975
Recurring | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Cash equivalents 66,423 48,770
Recurring | U.S. treasury notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Cash equivalents   42,997
Recurring | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Total 66,423 48,770
Recurring | Level 1 | U.S. treasury notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Marketable securities 0 0
Recurring | Level 1 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Cash equivalents 66,423 48,770
Recurring | Level 1 | U.S. treasury notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Cash equivalents   0
Recurring | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Total 94,468 135,972
Recurring | Level 2 | U.S. treasury notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Marketable securities 94,468 92,975
Recurring | Level 2 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Cash equivalents 0 0
Recurring | Level 2 | U.S. treasury notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Cash equivalents   42,997
Recurring | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Total 0 0
Recurring | Level 3 | U.S. treasury notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Marketable securities 0 0
Recurring | Level 3 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Cash equivalents $ 0 0
Recurring | Level 3 | U.S. treasury notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Cash equivalents   $ 0
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment, Net - Summary of Property and Equipment Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization    
Financing lease right-of-use asset $ 384 $ 0
Property plant and equipment including finance right of use assets, gross 22,368 21,631
Less: Accumulated depreciation and amortization (2,875) (2,103)
Property and equipment, net 19,493 19,528
Laboratory equipment    
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization    
Property, Plant and Equipment, Gross 3,998 3,740
Furniture and fixtures    
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization    
Property, Plant and Equipment, Gross 815 815
Computer equipment and software    
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization    
Property, Plant and Equipment, Gross 100 100
Leasehold improvements    
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization    
Property, Plant and Equipment, Gross 17,024 16,961
Assets not yet placed in service    
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization    
Property, Plant and Equipment, Gross $ 47 $ 15
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment, Net - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Property, Plant and Equipment [Abstract]    
Depreciation and amortization expense $ 772 $ 255
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Accrued employee compensation and benefits $ 978 $ 3,513
Accrued tenant improvements 913 2,385
Accrued external research and development expenses 2,477 2,146
Accrued professional fees 620 979
Other 138 138
Accrued Liabilities, Current, Total $ 5,126 $ 9,161
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Notes Payable - Summary of Long Term Debt (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Debt Disclosure [Abstract]    
Principal amount of long-term debt $ 20,000,000 $ 20,000,000
Less: Current portion of long-term debt 0 0
Long-term debt, net of current portion 20,000,000 20,000,000
Final payment fee 1,000,000 1,000,000
Debt discount, net of accretion (1,261,000) (1,346,000)
Long-term debt, net of discount and current portion $ 19,739,000 $ 19,654,000
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Notes Payable - Additional Information (Details) - USD ($)
 3 Months Ended
Nov. 19, 2020
Mar. 31, 2021
Dec. 31, 2020
Short-term Debt      
Principal borrowing amount   $ 20,000,000 $ 20,000,000
Oxford Finance LLC      
Short-term Debt      
Debt instrument, interest rate, stated percentage 8.00% 8.00%  
Debt, final payment fee percentage 5.00% 5.00%  
Class of warrant or right, number of securities called by warrants or rights (shares)   18,445  
Warrants issue price ( per share)   $ 16.26  
Warrants exercisable term   10 years  
Warrant fair value $ 200,000    
Debt instrument, term   5 years  
Payment of notes payable issuance costs   $ 200,000  
Debt, weighted average interest rate   9.70%  
Oxford Finance LLC | Period One      
Short-term Debt      
Prepayment fee (percent)   2.00%  
Oxford Finance LLC | Period One | Maximum      
Short-term Debt      
Prepayment period (months)   12 months  
Oxford Finance LLC | Period Two      
Short-term Debt      
Prepayment fee (percent)   1.00%  
Oxford Finance LLC | Period Two | Minimum      
Short-term Debt      
Prepayment period (months)   12 months  
Oxford Finance LLC | Period Two | Maximum      
Short-term Debt      
Prepayment period (months)   24 months  
Oxford Finance LLC | Period Three      
Short-term Debt      
Prepayment fee (percent)   0.50%  
Oxford Finance LLC | Period Three | Minimum      
Short-term Debt      
Prepayment period (months)   24 months  
Oxford Finance LLC | LIBOR      
Short-term Debt      
Debt instrument, basis spread on variable rate 7.84%    
Term Loan A      
Short-term Debt      
Principal borrowing amount   $ 20,000,000.0  
Term Loan B | Oxford Finance LLC      
Short-term Debt      
Additional borrowing capacity $ 5,000,000.0    
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Notes Payable - Summary of Future Principal Payments Due (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Long-term Debt, Fiscal Year Maturity    
Remainder of 2021 (nine months) $ 0  
2022 0  
2023 833  
2024 10,000  
2025 9,167  
Long-term debt, net of current portion $ 20,000 $ 20,000
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Common Stock and Net Loss Per Share - Earnings Per Share Diluted Anti Dilutive Impact (Details)
 3 Months Ended
Mar. 31, 2021
vote
shares
Mar. 31, 2020
shares
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Anti-dilutive shares excluded from the calculation of earnings per share (shares) 6,321,699 19,936,239
Voting rights per share (per share) | vote 1  
Stock options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Anti-dilutive shares excluded from the calculation of earnings per share (shares) 6,303,254 3,785,380
Warrants to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Anti-dilutive shares excluded from the calculation of earnings per share (shares) 18,445 0
Convertible preferred stock (as converted to common stock)    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Anti-dilutive shares excluded from the calculation of earnings per share (shares) 0 15,467,863
Warrants to purchase convertible preferred stock (as converted to common stock)    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Anti-dilutive shares excluded from the calculation of earnings per share (shares) 0 14,076
Unvested restricted common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Anti-dilutive shares excluded from the calculation of earnings per share (shares) 0 668,920
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 01, 2021
Mar. 31, 2021
Oct. 21, 2020
Share-based Payment Arrangement      
Unrecognized compensation costs related to unvested options and unvested restricted stock   $ 26.3  
Weighted average period of unrecognized compensation costs   3 years 3 months 18 days  
2020 Equity Incentive Plan      
Share-based Payment Arrangement      
Number of shares authorized   5,078,295 2,200,000
Common stock shares available for grant   2,380,492  
Annual share percentage increase (percent)     4.00%
Number of additional shares authorized 1,471,576    
Award vesting period   4 years  
Expiration period   10 years  
2020 Employee Stock Purchase Plan      
Share-based Payment Arrangement      
Number of shares authorized   3,220,520 360,000
Annual share percentage increase (percent)     1.00%
Number of additional shares authorized 367,894    
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation - Summary of Stock-based compensation expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Share-based Payment Arrangement    
Stock-based compensation expense $ 1,888 $ 517
Research and development expenses    
Share-based Payment Arrangement    
Stock-based compensation expense 1,014 327
General and administrative expenses    
Share-based Payment Arrangement    
Stock-based compensation expense $ 874 $ 190
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreement - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Jul. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative      
Upfront payment received from Merck $ 15,000 $ 15,000  
Deferred revenue   15,000  
Unsatisfied portion of the performance obligation   14,300  
Revenue   286 $ 0
Maximum | Sales based      
Collaborative Arrangement and Arrangement Other than Collaborative      
Amount receivable for achievement of milestones   165,000  
Research Development And Regulatory | Maximum      
Collaborative Arrangement and Arrangement Other than Collaborative      
Amount receivable for achievement of milestones   245,000  
Merck Collaboration Agreement      
Collaborative Arrangement and Arrangement Other than Collaborative      
Revenue   $ 300  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Additional Information (Details)
$ in Thousands
 3 Months Ended 96 Months Ended
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2027
USD ($)
Feb. 28, 2021
ft²
Dec. 31, 2020
USD ($)
Jun. 29, 2020
USD ($)
Apr. 30, 2020
ft²
Jan. 01, 2020
USD ($)
Oct. 31, 2019
USD ($)
ft²
Lessee, Lease, Description                  
Operating lease right-of-use assets $ 41,742       $ 42,804        
Operating lease liability 62,331                
Future sublease income outstanding 2,600                
Sublease income recorded as other income $ 600                
Finance lease contract term (years) 3 years                
Financing lease right-of-use asset $ 400                
Finance lease liability 300                
Office and Laboratory Space In Cambridge, Massachusetts                  
Lessee, Lease, Description                  
Area of leased property | ft²                 81,441
Operating lease term (years)                 8 years
Operating lease term extension (years)                 5 years
Reimbursements from lessor $ 1,500 $ 700              
Operating lease right-of-use assets               $ 38,600  
Operating lease liability               $ 38,300  
Office Space In Cambridge, Massachusetts                  
Lessee, Lease, Description                  
Area of leased property | ft²             16,843    
Term of property subleased under operating lease             2 years    
Additional Office Space In Cambridge, Massachusetts                  
Lessee, Lease, Description                  
Area of leased property | ft²       2,980          
Maximum | Office and Laboratory Space In Cambridge, Massachusetts                  
Lessee, Lease, Description                  
Leasehold improvements landlord allowance                 $ 3,000
Leasehold improvements landlord allowance to be repaid                 $ 16,300
Forecast | Office and Laboratory Space In Cambridge, Massachusetts                  
Lessee, Lease, Description                  
Operating lease rent payments     $ 60,300            
Adjustments | Office and Laboratory Space In Cambridge, Massachusetts                  
Lessee, Lease, Description                  
Operating lease right-of-use assets           $ 7,400      
Operating lease liability           $ 7,400      
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Summary of Lease Cost (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Leases [Abstract]    
Operating lease cost $ 1,887 $ 1,258
Short-term lease cost 0 27
Variable lease cost 763 236
Total $ 2,650 $ 1,521
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Leases [Abstract]    
Cash paid for amounts included in the measurement of operating lease liabilities $ 2,371 $ 456
Operating lease liabilities arising from obtaining right-of-use assets 0 38,306
Financing lease liabilities arising from obtaining right-of-use assets $ 330 $ 0
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Leases (Details)
Mar. 31, 2021
Dec. 31, 2020
Leases [Abstract]    
Weighted-average remaining lease term - operating leases (in years) 7 years 4 months 24 days 7 years 8 months 12 days
Weighted-average discount rate - operating leases 5.35% 5.35%
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Summary of Minimum Lease Payment (Details)
$ in Thousands
Mar. 31, 2021
USD ($)
Leases [Abstract]  
Remainder of 2021 (nine months) $ 7,391
2022 10,005
2023 10,115
2024 10,355
2025 10,603
Thereafter 30,521
Total future minimum lease payments 78,990
Less: imputed interest (14,261)
Less: estimated lease incentives (2,398)
Total operating lease liabilities $ 62,331
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Summary of Operating Lease Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Leases [Abstract]    
Current operating lease liabilities $ 5,783 $ 3,981
Operating lease liabilities, net of current portion 56,548 $ 58,361
Total operating lease liabilities $ 62,331  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies (Details) - Stanford - Maximum
$ in Millions
 3 Months Ended
Mar. 31, 2021
USD ($)
Commitments And Contingencies  
Annual license maintenance fees $ 0.1
Milestones payable upon event $ 1.1
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Related Parties (Details) - USD ($)
 1 Months Ended 3 Months Ended
Oct. 31, 2015
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Related Party Transaction        
Accounts payable   $ 2,911,000   $ 3,680,000
Flagship Pioneering        
Related Party Transaction        
Service agreement term 5 years      
Payments made to related party under service agreement   0 $ 200,000  
Accounts payable   0   $ 0
Scientific Founder        
Related Party Transaction        
Service agreement term 5 years      
Payments made to related party under service agreement   $ 100,000 $ 100,000  
EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 134 294 1 false 49 0 false 6 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.foghorntx.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements Of Operations And Comprehensive Loss Sheet http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements Of Operations And Comprehensive Loss Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity Sheet http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) Sheet http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Parenthetical) Statements 7 false false R8.htm 2101101 - Disclosure - Nature of Business and Basis of Presentation Sheet http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentation Nature of Business and Basis of Presentation Notes 8 false false R9.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.foghorntx.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2105103 - Disclosure - Marketable Securities and Fair Value Measurements Sheet http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurements Marketable Securities and Fair Value Measurements Notes 10 false false R11.htm 2109104 - Disclosure - Property and Equipment, Net Sheet http://www.foghorntx.com/role/PropertyandEquipmentNet Property and Equipment, Net Notes 11 false false R12.htm 2113105 - Disclosure - Accrued Expenses Sheet http://www.foghorntx.com/role/AccruedExpenses Accrued Expenses Notes 12 false false R13.htm 2116106 - Disclosure - Notes Payable Notes http://www.foghorntx.com/role/NotesPayable Notes Payable Notes 13 false false R14.htm 2121107 - Disclosure - Common Stock and Net Loss Per Share Sheet http://www.foghorntx.com/role/CommonStockandNetLossPerShare Common Stock and Net Loss Per Share Notes 14 false false R15.htm 2124108 - Disclosure - Stock-Based Compensation Sheet http://www.foghorntx.com/role/StockBasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 2128109 - Disclosure - Collaboration Agreement Sheet http://www.foghorntx.com/role/CollaborationAgreement Collaboration Agreement Notes 16 false false R17.htm 2130110 - Disclosure - Leases Sheet http://www.foghorntx.com/role/Leases Leases Notes 17 false false R18.htm 2138111 - Disclosure - Commitments and Contingencies Sheet http://www.foghorntx.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 18 false false R19.htm 2140112 - Disclosure - Defined Contribution Plan Sheet http://www.foghorntx.com/role/DefinedContributionPlan Defined Contribution Plan Notes 19 false false R20.htm 2141113 - Disclosure - Related Parties Sheet http://www.foghorntx.com/role/RelatedParties Related Parties Notes 20 false false R21.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.foghorntx.com/role/SummaryofSignificantAccountingPolicies 21 false false R22.htm 2306301 - Disclosure - Marketable Securities and Fair Value Measurements (Tables) Sheet http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsTables Marketable Securities and Fair Value Measurements (Tables) Tables http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurements 22 false false R23.htm 2310302 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.foghorntx.com/role/PropertyandEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.foghorntx.com/role/PropertyandEquipmentNet 23 false false R24.htm 2314303 - Disclosure - Accrued Expenses (Tables) Sheet http://www.foghorntx.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://www.foghorntx.com/role/AccruedExpenses 24 false false R25.htm 2317304 - Disclosure - Notes Payable (Tables) Notes http://www.foghorntx.com/role/NotesPayableTables Notes Payable (Tables) Tables http://www.foghorntx.com/role/NotesPayable 25 false false R26.htm 2322305 - Disclosure - Common Stock and Net Loss Per Share (Tables) Sheet http://www.foghorntx.com/role/CommonStockandNetLossPerShareTables Common Stock and Net Loss Per Share (Tables) Tables http://www.foghorntx.com/role/CommonStockandNetLossPerShare 26 false false R27.htm 2325306 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.foghorntx.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.foghorntx.com/role/StockBasedCompensation 27 false false R28.htm 2331307 - Disclosure - Leases (Tables) Sheet http://www.foghorntx.com/role/LeasesTables Leases (Tables) Tables http://www.foghorntx.com/role/Leases 28 false false R29.htm 2402401 - Disclosure - Nature of Business and Basis of Presentation (Details) Sheet http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails Nature of Business and Basis of Presentation (Details) Details http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentation 29 false false R30.htm 2407402 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Available for Sale Marketable Securities By Security Type (Details) Sheet http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails Marketable Securities and Fair Value Measurements - Summary of Available for Sale Marketable Securities By Security Type (Details) Details 30 false false R31.htm 2408403 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails Marketable Securities and Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 31 false false R32.htm 2411404 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment Net (Details) Sheet http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails Property and Equipment, Net - Summary of Property and Equipment Net (Details) Details 32 false false R33.htm 2412405 - Disclosure - Property and Equipment, Net - Additional Information (Details) Sheet http://www.foghorntx.com/role/PropertyandEquipmentNetAdditionalInformationDetails Property and Equipment, Net - Additional Information (Details) Details 33 false false R34.htm 2415406 - Disclosure - Accrued Expenses (Details) Sheet http://www.foghorntx.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://www.foghorntx.com/role/AccruedExpensesTables 34 false false R35.htm 2418407 - Disclosure - Notes Payable - Summary of Long Term Debt (Details) Notes http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails Notes Payable - Summary of Long Term Debt (Details) Details 35 false false R36.htm 2419408 - Disclosure - Notes Payable - Additional Information (Details) Notes http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails Notes Payable - Additional Information (Details) Details 36 false false R37.htm 2420409 - Disclosure - Notes Payable - Summary of Future Principal Payments Due (Details) Notes http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails Notes Payable - Summary of Future Principal Payments Due (Details) Details 37 false false R38.htm 2423410 - Disclosure - Common Stock and Net Loss Per Share - Earnings Per Share Diluted Anti Dilutive Impact (Details) Sheet http://www.foghorntx.com/role/CommonStockandNetLossPerShareEarningsPerShareDilutedAntiDilutiveImpactDetails Common Stock and Net Loss Per Share - Earnings Per Share Diluted Anti Dilutive Impact (Details) Details 38 false false R39.htm 2426411 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 39 false false R40.htm 2427412 - Disclosure - Stock-Based Compensation - Summary of Stock-based compensation expense (Details) Sheet http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails Stock-Based Compensation - Summary of Stock-based compensation expense (Details) Details 40 false false R41.htm 2429413 - Disclosure - Collaboration Agreement - Additional Information (Details) Sheet http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails Collaboration Agreement - Additional Information (Details) Details 41 false false R42.htm 2432414 - Disclosure - Leases - Additional Information (Details) Sheet http://www.foghorntx.com/role/LeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 42 false false R43.htm 2433415 - Disclosure - Leases - Summary of Lease Cost (Details) Sheet http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails Leases - Summary of Lease Cost (Details) Details 43 false false R44.htm 2434416 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details) Sheet http://www.foghorntx.com/role/LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details) Details 44 false false R45.htm 2435417 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Leases (Details) Sheet http://www.foghorntx.com/role/LeasesSummaryofWeightedAverageRemainingLeaseTermandDiscountRateLeasesDetails Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Leases (Details) Details 45 false false R46.htm 2436418 - Disclosure - Leases - Summary of Minimum Lease Payment (Details) Sheet http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails Leases - Summary of Minimum Lease Payment (Details) Details 46 false false R47.htm 2437419 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details) Sheet http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails Leases - Summary of Operating Lease Liabilities (Details) Details 47 false false R48.htm 2439420 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.foghorntx.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.foghorntx.com/role/CommitmentsandContingencies 48 false false R49.htm 2442421 - Disclosure - Related Parties (Details) Sheet http://www.foghorntx.com/role/RelatedPartiesDetails Related Parties (Details) Details http://www.foghorntx.com/role/RelatedParties 49 false false All Reports Book All Reports fhtx-20210331.htm fhtx-20210331.xsd fhtx-20210331_cal.xml fhtx-20210331_def.xml fhtx-20210331_lab.xml fhtx-20210331_pre.xml fhtx-20210331xex311.htm fhtx-20210331xex312.htm fhtx-20210331xex321.htm fhtx-20210331xex322.htm http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "fhtx-20210331.htm": { "axisCustom": 2, "axisStandard": 19, "contextCount": 134, "dts": { "calculationLink": { "local": [ "fhtx-20210331_cal.xml" ] }, "definitionLink": { "local": [ "fhtx-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "fhtx-20210331.htm" ] }, "labelLink": { "local": [ "fhtx-20210331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "fhtx-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "fhtx-20210331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 379, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 5 }, "keyCustom": 25, "keyStandard": 269, "memberCustom": 19, "memberStandard": 28, "nsprefix": "fhtx", "nsuri": "http://www.foghorntx.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.foghorntx.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "fhtx:MarketableSecuritiesAndFairValueMeasurementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - Marketable Securities and Fair Value Measurements", "role": "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurements", "shortName": "Marketable Securities and Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "fhtx:MarketableSecuritiesAndFairValueMeasurementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109104 - Disclosure - Property and Equipment, Net", "role": "http://www.foghorntx.com/role/PropertyandEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113105 - Disclosure - Accrued Expenses", "role": "http://www.foghorntx.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116106 - Disclosure - Notes Payable", "role": "http://www.foghorntx.com/role/NotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121107 - Disclosure - Common Stock and Net Loss Per Share", "role": "http://www.foghorntx.com/role/CommonStockandNetLossPerShare", "shortName": "Common Stock and Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124108 - Disclosure - Stock-Based Compensation", "role": "http://www.foghorntx.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128109 - Disclosure - Collaboration Agreement", "role": "http://www.foghorntx.com/role/CollaborationAgreement", "shortName": "Collaboration Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130110 - Disclosure - Leases", "role": "http://www.foghorntx.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138111 - Disclosure - Commitments and Contingencies", "role": "http://www.foghorntx.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140112 - Disclosure - Defined Contribution Plan", "role": "http://www.foghorntx.com/role/DefinedContributionPlan", "shortName": "Defined Contribution Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i5c41701fcfa34556be294b907faaeebe_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141113 - Disclosure - Related Parties", "role": "http://www.foghorntx.com/role/RelatedParties", "shortName": "Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)", "role": "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsTables", "shortName": "Marketable Securities and Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310302 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://www.foghorntx.com/role/PropertyandEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314303 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.foghorntx.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317304 - Disclosure - Notes Payable (Tables)", "role": "http://www.foghorntx.com/role/NotesPayableTables", "shortName": "Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322305 - Disclosure - Common Stock and Net Loss Per Share (Tables)", "role": "http://www.foghorntx.com/role/CommonStockandNetLossPerShareTables", "shortName": "Common Stock and Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325306 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.foghorntx.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331307 - Disclosure - Leases (Tables)", "role": "http://www.foghorntx.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i964f648e6d32425a918ffd7234a223ca_D20200701-20200731", "decimals": "-5", "first": true, "lang": "en-US", "name": "fhtx:ProceedsFromUpfrontPayment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Nature of Business and Basis of Presentation (Details)", "role": "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails", "shortName": "Nature of Business and Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i3dc2b3ed30bb426e9b5cd4be0789e606_D20201027-20201027", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Available for Sale Marketable Securities By Security Type (Details)", "role": "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails", "shortName": "Marketable Securities and Fair Value Measurements - Summary of Available for Sale Marketable Securities By Security Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "role": "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "shortName": "Marketable Securities and Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ib31b5c939c834ffda33df65982009737_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment Net (Details)", "role": "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails", "shortName": "Property and Equipment, Net - Summary of Property and Equipment Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "role": "http://www.foghorntx.com/role/PropertyandEquipmentNetAdditionalInformationDetails", "shortName": "Property and Equipment, Net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - Accrued Expenses (Details)", "role": "http://www.foghorntx.com/role/AccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418407 - Disclosure - Notes Payable - Summary of Long Term Debt (Details)", "role": "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails", "shortName": "Notes Payable - Summary of Long Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419408 - Disclosure - Notes Payable - Additional Information (Details)", "role": "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails", "shortName": "Notes Payable - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ie9a9c3b6f11f482388b69ec48aa04334_I20201119", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420409 - Disclosure - Notes Payable - Summary of Future Principal Payments Due (Details)", "role": "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails", "shortName": "Notes Payable - Summary of Future Principal Payments Due (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423410 - Disclosure - Common Stock and Net Loss Per Share - Earnings Per Share Diluted Anti Dilutive Impact (Details)", "role": "http://www.foghorntx.com/role/CommonStockandNetLossPerShareEarningsPerShareDilutedAntiDilutiveImpactDetails", "shortName": "Common Stock and Net Loss Per Share - Earnings Per Share Diluted Anti Dilutive Impact (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426411 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "role": "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements Of Operations And Comprehensive Loss", "role": "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statements Of Operations And Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427412 - Disclosure - Stock-Based Compensation - Summary of Stock-based compensation expense (Details)", "role": "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails", "shortName": "Stock-Based Compensation - Summary of Stock-based compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i22a49fecb1e24d47ad5e4c8fd341fdaf_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i964f648e6d32425a918ffd7234a223ca_D20200701-20200731", "decimals": "-5", "first": true, "lang": "en-US", "name": "fhtx:ProceedsFromUpfrontPayment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429413 - Disclosure - Collaboration Agreement - Additional Information (Details)", "role": "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails", "shortName": "Collaboration Agreement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432414 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433415 - Disclosure - Leases - Summary of Lease Cost (Details)", "role": "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails", "shortName": "Leases - Summary of Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "fhtx:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434416 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details)", "role": "http://www.foghorntx.com/role/LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails", "shortName": "Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "fhtx:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "fhtx:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435417 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Leases (Details)", "role": "http://www.foghorntx.com/role/LeasesSummaryofWeightedAverageRemainingLeaseTermandDiscountRateLeasesDetails", "shortName": "Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "fhtx:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "fhtx:OperatingLeaseLiabilityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436418 - Disclosure - Leases - Summary of Minimum Lease Payment (Details)", "role": "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails", "shortName": "Leases - Summary of Minimum Lease Payment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "fhtx:OperatingLeaseLiabilityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "fhtx:OperatingLeaseLiabilityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437419 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details)", "role": "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails", "shortName": "Leases - Summary of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "icd2137d3cd444031b93ae02c80c2389d_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "fhtx:AnnualLicenseMaintenanceFees", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439420 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "icd2137d3cd444031b93ae02c80c2389d_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "fhtx:AnnualLicenseMaintenanceFees", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442421 - Disclosure - Related Parties (Details)", "role": "http://www.foghorntx.com/role/RelatedPartiesDetails", "shortName": "Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "id9f51a071bed45fb84b1dde3ea8d08a0_D20151001-20151031", "decimals": null, "lang": "en-US", "name": "fhtx:ServiceAgreementTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i4d006e278f7e4ee6a517a2de6ff43836_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity", "role": "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity", "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i4d006e278f7e4ee6a517a2de6ff43836_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "fhtx:IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i90058e8dccac4a11896091618640ad50_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "role": "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "i8a644e1fbd914212a7fb0d96fcc65c8d_I20200331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Nature of Business and Basis of Presentation", "role": "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentation", "shortName": "Nature of Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.foghorntx.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "fhtx-20210331.htm", "contextRef": "ibceafffe973c456980a82edf0c8e916c_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 49, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Street Name" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol(s)" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "fhtx_AccruedResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.foghorntx.com/role/AccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Research And Development Expenses", "terseLabel": "Accrued external research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentExpenses", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "fhtx_AccruedTenantImprovements": { "auth_ref": [], "calculation": { "http://www.foghorntx.com/role/AccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Tenant Improvements", "label": "Accrued Tenant Improvements", "terseLabel": "Accrued tenant improvements" } } }, "localname": "AccruedTenantImprovements", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Office Space In Cambridge, Massachusetts", "label": "Additional Office Space In Cambridge, Massachusetts [Member]", "terseLabel": "Additional Office Space In Cambridge, Massachusetts" } } }, "localname": "AdditionalOfficeSpaceInCambridgeMassachusettsMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_AgreementsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreements.", "label": "Agreements [Axis]", "terseLabel": "Agreements [Axis]" } } }, "localname": "AgreementsAxis", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/RelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "fhtx_AgreementsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreements.", "label": "Agreements [Domain]", "terseLabel": "Agreements [Domain]" } } }, "localname": "AgreementsDomain", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/RelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fhtx_AnnualLicenseMaintenanceFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Annual license maintenance fees.", "label": "Annual License Maintenance Fees", "terseLabel": "Annual license maintenance fees" } } }, "localname": "AnnualLicenseMaintenanceFees", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "fhtx_AssetsNotYetPlacedInServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets Not Yet Placed In service[Member].", "label": "Assets Not Yet Placed In service [Member]", "terseLabel": "Assets not yet placed in service" } } }, "localname": "AssetsNotYetPlacedInServiceMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "fhtx_CashPaymentsRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments made during the period to related parties as part of a service or consulting agreement.", "label": "Cash Payments Related Party", "terseLabel": "Payments made to related party under service agreement" } } }, "localname": "CashPaymentsRelatedParty", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/RelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "fhtx_CollaborationAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration Agreement", "label": "Collaboration Agreement [Abstract]", "terseLabel": "Collaboration Agreement [Abstract]" } } }, "localname": "CollaborationAgreementAbstract", "nsuri": "http://www.foghorntx.com/20210331", "xbrltype": "stringItemType" }, "fhtx_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments And Contingencies", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "fhtx_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments And Contingencies", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "fhtx_CommonStockVotingRightsVotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Voting Rights, Votes", "label": "Common Stock, Voting Rights, Votes", "terseLabel": "Voting rights per share (per share)" } } }, "localname": "CommonStockVotingRightsVotes", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CommonStockandNetLossPerShareEarningsPerShareDilutedAntiDilutiveImpactDetails" ], "xbrltype": "integerItemType" }, "fhtx_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer equipment and software", "label": "Computer equipment and software [Member]", "terseLabel": "Computer equipment and software" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt, as a percentage of the amounts drawn under the Term Loan.", "label": "Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid Percentage", "terseLabel": "Debt, final payment fee percentage" } } }, "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "fhtx_FlagshipPioneeringMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Flagship Pioneering.", "label": "Flagship Pioneering [Member]", "terseLabel": "Flagship Pioneering" } } }, "localname": "FlagshipPioneeringMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/RelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fhtx_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in operating lease liabilities during the reporting period.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in right-of-use assets under an operating lease.", "label": "Increase Decrease In Operating Lease Right Of Use Asset", "terseLabel": "Noncash lease expense" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "fhtx_InterestIncomeAndOtherIncomeExpense": { "auth_ref": [], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income and income (expense) related to nonoperating activities, classified as other.", "label": "Interest Income And Other Income Expense", "terseLabel": "Interest income and other income (expense), net" } } }, "localname": "InterestIncomeAndOtherIncomeExpense", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "fhtx_LeaseholdImprovementsLandlordAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The monetary allowance granted by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenant's occupancy.", "label": "Leasehold Improvements Landlord Allowance", "terseLabel": "Leasehold improvements landlord allowance" } } }, "localname": "LeaseholdImprovementsLandlordAllowance", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An additional monetary allowance granted by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenant's occupancy. This additional amount will result in additional rent payments to the landlord.", "label": "Leasehold Improvements Landlord Allowance To Be Repaid", "terseLabel": "Leasehold improvements landlord allowance to be repaid" } } }, "localname": "LeaseholdImprovementsLandlordAllowanceToBeRepaid", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives": { "auth_ref": [], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of estimated lease incentives used by lessee to determine present value of operating lease payments.", "label": "Lessee Operating Lease Liability Estimated Lease Incentives", "negatedLabel": "Less: estimated lease incentives" } } }, "localname": "LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails" ], "xbrltype": "monetaryItemType" }, "fhtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails" ], "xbrltype": "monetaryItemType" }, "fhtx_LineOfCreditAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line Of Credit Additional Borrowing Capacity", "label": "Line Of Credit Additional Borrowing Capacity", "terseLabel": "Additional borrowing capacity" } } }, "localname": "LineOfCreditAdditionalBorrowingCapacity", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for marketable securities and fair value measurements.", "label": "Marketable Securities and Fair Value Measurements [Text Block]", "terseLabel": "Marketable Securities and Fair Value Measurements" } } }, "localname": "MarketableSecuritiesAndFairValueMeasurementsTextBlock", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "fhtx_MerckCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merck collaboration agreement.", "label": "Merck Collaboration Agreement [Member]", "terseLabel": "Merck Collaboration Agreement" } } }, "localname": "MerckCollaborationAgreementMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_MilestoneReceivableUponAchievement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of consideration to be received upon achievement of specified milestones.", "label": "Milestone Receivable Upon Achievement", "terseLabel": "Amount receivable for achievement of milestones" } } }, "localname": "MilestoneReceivableUponAchievement", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fhtx_MilestonesPayableUponEvent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount the Company will pay for regulatory milestones on each licensed product upon the occurrence of specific events as outlined in the license agreement.", "label": "Milestones Payable Upon Event", "terseLabel": "Milestones payable upon event" } } }, "localname": "MilestonesPayableUponEvent", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office and Laboratory Space In Cambridge, Massachusetts", "label": "Office and Laboratory Space In Cambridge, Massachusetts [Member]", "terseLabel": "Office and Laboratory Space In Cambridge, Massachusetts" } } }, "localname": "OfficeAndLaboratorySpaceInCambridgeMassachusettsMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_OfficeSpaceInCambridgeMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office Space In Cambridge, Massachusetts", "label": "Office Space In Cambridge, Massachusetts [Member]", "terseLabel": "Office Space In Cambridge, Massachusetts" } } }, "localname": "OfficeSpaceInCambridgeMassachusettsMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_OperatingLeaseLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of operating lease liabilities included in the consolidated balance sheet.", "label": "Operating Lease Liability [Table Text Block]", "terseLabel": "Summary of Operating Lease Liabilities" } } }, "localname": "OperatingLeaseLiabilityTableTextBlock", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "fhtx_OxfordFinanceLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oxford finance llc.", "label": "Oxford Finance LLC [Member]", "terseLabel": "Oxford Finance LLC" } } }, "localname": "OxfordFinanceLlcMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_PercentageOfPrepaymentFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee for prepayment of a loan, as a percentage of the principal amount being prepaid.", "label": "Percentage Of Prepayment Fee", "terseLabel": "Prepayment fee (percent)" } } }, "localname": "PercentageOfPrepaymentFee", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "fhtx_PrepaymentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment Period", "label": "Prepayment Period", "terseLabel": "Prepayment period (months)" } } }, "localname": "PrepaymentPeriod", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "fhtx_PrepaymentPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepayment Period [Axis]", "terseLabel": "Prepayment Period [Axis]" } } }, "localname": "PrepaymentPeriodAxis", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "fhtx_PrepaymentPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment Period [Domain]", "label": "Prepayment Period [Domain]", "terseLabel": "Prepayment Period [Domain]" } } }, "localname": "PrepaymentPeriodDomain", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_PrepaymentPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment Period One", "label": "Prepayment Period One [Member]", "terseLabel": "Period One" } } }, "localname": "PrepaymentPeriodOneMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_PrepaymentPeriodThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment Period Three", "label": "Prepayment Period Three [Member]", "terseLabel": "Period Three" } } }, "localname": "PrepaymentPeriodThreeMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_PrepaymentPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment Period Two", "label": "Prepayment Period Two [Member]", "terseLabel": "Period Two" } } }, "localname": "PrepaymentPeriodTwoMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_ProceedsFromUpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from upfront payment", "label": "Proceeds From Upfront Payment", "terseLabel": "Upfront payment received from Merck" } } }, "localname": "ProceedsFromUpfrontPayment", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails", "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "fhtx_ResearchDevelopmentAndRegulatoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research development and regulatory.", "label": "Research Development And Regulatory [Member]", "terseLabel": "Research Development And Regulatory" } } }, "localname": "ResearchDevelopmentAndRegulatoryMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental information for the statement of cash flows related to leases.", "label": "Schedule Of Supplemental Cash Flow Information Related To Leases [Table Text Block]", "terseLabel": "Summary of Supplemental Cash Flow Information Related to Leases" } } }, "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "fhtx_ScientificFounderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Scientific Founder.", "label": "Scientific Founder [Member]", "terseLabel": "Scientific Founder" } } }, "localname": "ScientificFounderMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/RelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fhtx_ServiceAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The term of a service agreement in 'PnYnMnDTnHnMnS' format.", "label": "Service agreement term", "terseLabel": "Service agreement term" } } }, "localname": "ServiceAgreementTerm", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/RelatedPartiesDetails" ], "xbrltype": "durationItemType" }, "fhtx_ShareBasedCompensationAnnualSharePercentageIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Annual Share Percentage Increase", "label": "Share-based Compensation, Annual Share Percentage Increase", "terseLabel": "Annual share percentage increase (percent)" } } }, "localname": "ShareBasedCompensationAnnualSharePercentageIncrease", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "fhtx_StanfordLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stanford License Agreement [Member]", "terseLabel": "Stanford" } } }, "localname": "StanfordLicenseAgreementMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "fhtx_TermLoanAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Term Loan A [Member]", "terseLabel": "Term Loan A" } } }, "localname": "TermLoanAMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_TermLoanBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Term Loan B [Member]", "terseLabel": "Term Loan B" } } }, "localname": "TermLoanBMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]", "terseLabel": "2020 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_TwoThousandTwentyEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan" } } }, "localname": "TwoThousandTwentyEquityIncentivePlanMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fhtx_WarrantsIssuePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per unit amount of warrant issued.", "label": "Warrants Issue Price Per Share", "terseLabel": "Warrants issue price ( per share)" } } }, "localname": "WarrantsIssuePricePerShare", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "fhtx_WarrantsOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants One", "label": "Warrants One [Member]", "terseLabel": "Warrants to purchase convertible preferred stock (as converted to common stock)" } } }, "localname": "WarrantsOneMember", "nsuri": "http://www.foghorntx.com/20210331", "presentation": [ "http://www.foghorntx.com/role/CommonStockandNetLossPerShareEarningsPerShareDilutedAntiDilutiveImpactDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r200", "r202", "r303", "r304", "r305", "r306", "r307", "r308", "r327", "r364", "r365" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails", "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails", "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails", "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r200", "r202", "r303", "r304", "r305", "r306", "r307", "r308", "r327", "r364", "r365" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r180", "r200", "r202", "r303", "r304", "r305", "r306", "r307", "r308", "r327", "r364", "r365" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails", "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails", "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails", "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r180", "r200", "r202", "r303", "r304", "r305", "r306", "r307", "r308", "r327", "r364", "r365" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails", "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails", "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails", "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r161", "r201", "r296" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets", "http://www.foghorntx.com/role/RelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r73" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedTerseLabel": "Accretion of discount on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.foghorntx.com/role/AccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Accrued Liabilities, Current, Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/AccruedExpensesDetails", "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r6", "r7", "r34" ], "calculation": { "http://www.foghorntx.com/role/AccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r45", "r46", "r47", "r358", "r370", "r371" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r44", "r47", "r48", "r87", "r88", "r89", "r238", "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r17", "r219" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r87", "r88", "r89", "r216", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r204", "r205", "r221", "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive shares excluded from the calculation of earnings per share (shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CommonStockandNetLossPerShareEarningsPerShareDilutedAntiDilutiveImpactDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CommonStockandNetLossPerShareEarningsPerShareDilutedAntiDilutiveImpactDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CommonStockandNetLossPerShareEarningsPerShareDilutedAntiDilutiveImpactDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CommonStockandNetLossPerShareEarningsPerShareDilutedAntiDilutiveImpactDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of leased property" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r82", "r116", "r119", "r125", "r140", "r235", "r239", "r252", "r342", "r355" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r40", "r82", "r140", "r235", "r239", "r252" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r135" ], "calculation": { "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r136" ], "calculation": { "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r133", "r147" ], "calculation": { "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r131", "r134", "r147", "r346" ], "calculation": { "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Estimated Fair Value", "verboseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails", "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r86", "r111" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Nature of Business and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r76", "r77", "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r25", "r74" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets", "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r68", "r74", "r79" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r68", "r253" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "verboseLabel": "Supplemental disclosure of noncash investing and financing information:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r80", "r82", "r99", "r100", "r101", "r103", "r105", "r108", "r109", "r110", "r140", "r252" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Class of warrant or right, number of securities called by warrants or rights (shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r229", "r230", "r232" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration Agreement" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r38", "r160", "r347", "r361" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r157", "r158", "r159", "r162" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r167" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (Shares)", "periodStartLabel": "Beginning balance (Shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 175,000,000 shares authorized at March\u00a031, 2021 and December\u00a031, 2020; 36,826,775 shares issued and outstanding at March 31, 2021; 36,790,946 shares issued and outstanding at December\u00a031, 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r51", "r53", "r54", "r57", "r350", "r363" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r174", "r175", "r179" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r174", "r175", "r179" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r174", "r175", "r179" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Series A-1, A-2 and B Convertible Preferred Stock", "verboseLabel": "Convertible preferred stock (as converted to common stock)" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CommonStockandNetLossPerShareEarningsPerShareDilutedAntiDilutiveImpactDetails", "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r11", "r12", "r13", "r343", "r344", "r354" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r262", "r264" ], "calculation": { "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal borrowing amount", "verboseLabel": "Principal amount of long-term debt" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails", "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "auth_ref": [], "calculation": { "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.", "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid", "terseLabel": "Final payment fee" } } }, "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r261", "r264" ], "calculation": { "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Debt discount, net of accretion" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Summary of Available for Sale Marketable Securities By Security Type" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r72", "r115" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.foghorntx.com/role/PropertyandEquipmentNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share attributable to common stockholders\u2014basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.foghorntx.com/role/AccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation costs related to unvested options and unvested restricted stock" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period of unrecognized compensation costs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options to purchase common stock" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CommonStockandNetLossPerShareEarningsPerShareDilutedAntiDilutiveImpactDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Laboratory equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r87", "r88", "r89", "r91", "r96", "r98", "r107", "r141", "r167", "r172", "r216", "r217", "r218", "r227", "r228", "r254", "r255", "r256", "r257", "r258", "r259", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r72", "r166" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 }, "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of preferred stock warrant liability", "terseLabel": "Change in fair value of preferred stock warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r242", "r243", "r244", "r248" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "verboseLabel": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasis[Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r242", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r181", "r183", "r184", "r185", "r186", "r187", "r188", "r196", "r243", "r300", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r242", "r243", "r245", "r246", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r181", "r183", "r188", "r196", "r243", "r300" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r181", "r183", "r188", "r196", "r243", "r301" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r181", "r183", "r184", "r185", "r186", "r187", "r188", "r196", "r243", "r302" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r181", "r183", "r184", "r185", "r186", "r187", "r188", "r196", "r300", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r247", "r249" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r266", "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Finance lease liability" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r266" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Financing lease liability" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r266" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Financing lease liability, net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r265" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Financing lease right-of-use asset" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [ "r265" ], "calculation": { "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "Financing lease right-of-use asset" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r137", "r138", "r142", "r143", "r144", "r145", "r146", "r148", "r149", "r150", "r151", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r60" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails", "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails", "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r71" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r71" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r71" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r55", "r114", "r260", "r263", "r351" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r67", "r69", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r282", "r284" ], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).", "label": "Leaseholds and Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdsAndLeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Finance Lease, Term of Contract", "terseLabel": "Finance lease contract term (years)" } } }, "localname": "LesseeFinanceLeaseTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of Minimum Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r283" ], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r283" ], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r283" ], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r283" ], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r283" ], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r283" ], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2021 (nine months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r283" ], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease term extension (years)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease term (years)" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "terseLabel": "Future sublease income outstanding" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Term of property subleased under operating lease" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r33", "r82", "r120", "r140", "r236", "r239", "r240", "r252" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r82", "r140", "r252", "r345", "r360" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r35", "r82", "r140", "r236", "r239", "r240", "r252" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r13", "r164", "r344", "r356" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term Debt", "totalLabel": "Long-term debt, net of discount and current portion" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets", "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Long-term Debt, Fiscal Year Maturity" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "verboseLabel": "Less: Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r85", "r163" ], "calculation": { "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r85", "r163" ], "calculation": { "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r85", "r163" ], "calculation": { "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r85", "r163" ], "calculation": { "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r85" ], "calculation": { "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "Remainder of 2021 (nine months)" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "totalLabel": "Long-term debt, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableSummaryofFuturePrincipalPaymentsDueDetails", "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.", "label": "Long-term Debt, Weighted Average Interest Rate, over Time", "terseLabel": "Debt, weighted average interest rate" } } }, "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r348" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable Securities, Unrealized Gain (Loss)", "terseLabel": "Unrealized gains on marketable securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r68", "r70", "r73" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r49", "r52", "r56", "r73", "r82", "r90", "r92", "r93", "r94", "r95", "r97", "r98", "r102", "r116", "r118", "r121", "r124", "r126", "r140", "r252", "r349", "r362" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently issued accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r61" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r116", "r118", "r121", "r124", "r126" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r274", "r284" ], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease rent payments" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r266" ], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails", "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails", "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r266" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities", "verboseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets", "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r266" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets", "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r269", "r278" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r265" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets", "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r281", "r284" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofWeightedAverageRemainingLeaseTermandDiscountRateLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r280", "r284" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofWeightedAverageRemainingLeaseTermandDiscountRateLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r6", "r7", "r8", "r34" ], "calculation": { "http://www.foghorntx.com/role/AccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r42", "r43", "r45" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Unrealized losses on marketable securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r50", "r53", "r233", "r234", "r237" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r72" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid-in-Kind Interest", "terseLabel": "Noncash interest expense" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "auth_ref": [ "r62", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.", "label": "Payments for (Proceeds from) Tenant Allowance", "negatedTerseLabel": "Reimbursements from lessor" } } }, "localname": "PaymentsForProceedsFromTenantAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "terseLabel": "Payment of notes payable issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r132" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r63" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r180", "r182", "r188", "r189", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r203" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Defined Contribution Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/DefinedContributionPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r206", "r214" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r15" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 25,000,000 shares authorized at March 31, 2021 and December\u00a031, 2020; no shares issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r23", "r24" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from the sale of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r65", "r215" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r153", "r267", "r273" ], "calculation": { "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedTerseLabel": "Less: Accumulated depreciation and amortization" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r41", "r154", "r273" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets", "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]", "terseLabel": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r9", "r152", "r265" ], "calculation": { "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "totalLabel": "Property plant and equipment including finance right of use assets, gross" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r27", "r154" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r156", "r388", "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r26", "r152" ], "calculation": { "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r9", "r154" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property and Equipment Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r9", "r152" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r190", "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/RelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r190", "r290", "r293", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r288", "r289", "r291", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/RelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails", "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails", "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r224", "r399" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r79", "r341", "r357" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash (current and non-current)" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r5", "r10", "r79", "r387" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted common stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CommonStockandNetLossPerShareEarningsPerShareDilutedAntiDilutiveImpactDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r172", "r219", "r359", "r369", "r371" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets", "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r87", "r88", "r89", "r91", "r96", "r98", "r141", "r216", "r217", "r218", "r227", "r228", "r366", "r368" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "verboseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r112", "r113", "r117", "r122", "r123", "r127", "r128", "r129", "r177", "r178", "r328" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Collaboration revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails", "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r176" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Unsatisfied portion of the performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r279", "r284" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Financing lease liabilities arising from obtaining right-of-use assets" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r279", "r284" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Sale of stock consideration received on the transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "verboseLabel": "Sale of stock issue price per share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales based" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Domain member used to indicate figures that are adjustments during a period or as of a point in time. This domain member would never be expected to appear in a relationship group without the \"Scenario, Previously Reported\" Member with the same parent.", "label": "Scenario, Adjustment [Member]", "terseLabel": "Adjustments" } } }, "localname": "ScenarioAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CommonStockandNetLossPerShareEarningsPerShareDilutedAntiDilutiveImpactDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Earnings Per Share Diluted Anti Dilutive Impact" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CommonStockandNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r37", "r84", "r168", "r169", "r170", "r171", "r261", "r262", "r264", "r353" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Summary of Long Term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r205", "r212", "r220" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r205", "r212", "r220" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Summary of Future Long Term Loan Principal Payments Due" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r27", "r154" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r83", "r292", "r293" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/RelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]", "terseLabel": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r71" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Common stock shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]", "terseLabel": "Short-term Debt" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r275", "r284" ], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r14", "r15", "r16", "r80", "r82", "r99", "r100", "r101", "r103", "r105", "r108", "r109", "r110", "r140", "r167", "r252" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r39", "r87", "r88", "r89", "r91", "r96", "r98", "r107", "r141", "r167", "r172", "r216", "r217", "r218", "r227", "r228", "r254", "r255", "r256", "r257", "r258", "r259", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r87", "r88", "r89", "r107", "r328" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r15", "r16", "r167", "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued during the period shares new issues shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r15", "r16", "r167", "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r167", "r172", "r210" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r39", "r167", "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r20", "r21", "r82", "r130", "r140", "r252" ], "calculation": { "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets", "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r81", "r172", "r173" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Common Stock and Net Loss Per Share" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CommonStockandNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r277", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sublease income recorded as other income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r137", "r138", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryNotesSecuritiesMember": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Notes Securities [Member]", "terseLabel": "U.S. treasury notes (due within one year)" } } }, "localname": "USTreasuryNotesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r181", "r196", "r352" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury notes" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r276", "r284" ], "calculation": { "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CommonStockandNetLossPerShareEarningsPerShareDilutedAntiDilutiveImpactDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants exercisable term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of warrants not settleable in cash classified as equity.", "label": "Warrants Not Settleable in Cash, Fair Value Disclosure", "terseLabel": "Warrant fair value" } } }, "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average common shares outstanding\u2014basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.foghorntx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919359-209981" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r401": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r402": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r403": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r404": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r405": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r406": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" } }, "version": "2.1" } ZIP 67 0001628280-21-009813-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-21-009813-xbrl.zip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�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end